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ABSTRACT 
 
 
 
Differential Cytokine mRNA Expression Induced by Binding of Virulent and Avirulent 
Molecularly Cloned Equine Infectious Anemia Viruses to Equine Macrophages.  
(August 2003) 
Wah-Seng Lim, B.A., University of Kansas 
Chair of Advisory Committee: Dr. Judith M. Ball 
 
Equine infectious anemia virus (EIAV) causes rapid development of acute 
disease followed by recurring episodes of fever, thrombocytopenia and viremia, termed 
chronic EIA.  Most infected horses control the virus by immune mechanisms and 
become inapparent carriers.  To further our understanding of the equine immune 
response to EIAV, a multi-probe ribonuclease protection assay (RPA) was developed to 
quantitate equine-specific cytokine mRNAs.  Eleven template plasmids specific to ten 
equine cytokine genes and the β-actin gene were generated, from which radiolabeled 
anti-sense RNA probes were produced.  The RPA simultaneously quantitated mRNA 
levels of interleukin (IL)-1α, IL-1β, IL-6, IL-8, IL-10, IL-12 p35, IL-12 p40, interferon 
(IFN)-γ, transforming growth factor (TGF)-1β and tumor necrosis factor (TNF)-α in 
equine peripheral blood mononuclear cells and equine monocyte-derived macrophages 
(EMDM).  The assay detected as few as 5×105 RNA molecules and displayed 
coefficients of variation of 0.03-0.08 when normalized to β-actin expression.  Using this 
RPA, cytokine expression in EMDM infected with 2 molecularly cloned viruses 
 iv
(EIAV17 and EIAV19) was determined.  EIAV17 varies from EIAV19 only in env, rev and 
LTR and causes fatal disease in Shetland ponies.  When added to EMDM cultures, 
virulent EIAV17 stimulated expression of IL-1α, IL-1β, IL-6, IL-10 and TNF-α.  These 
cytokine mRNAs were significantly elevated by 0.5 to 1 hr post infection (hpi) and 
returned to basal levels by 12 to 24 hpi, indicating modulation by early event(s), such as 
receptor binding.  In contrast to EIAV17, EIAV19 is avirulent in vivo and failed to induce 
any of the tested cytokines in EMDM.  These data show a direct correlation between the 
virulence of the EIAV clone and the induction of cytokines.  The cytokines stimulated 
by EIAV17 may contribute to EIA-associated symptoms, enhance viral replication in the 
host, and regulate the host immune response.  To determine whether cytokine induction 
requires EIAV17 replication, EMDM cultures were exposed to UV-inactivated EIAV17 
and cytokine induction was monitored.  UV-inactivation did not block cytokine 
induction by EIAV17, suggesting dispensability of viral replication.  Given that EIAV17 
induces cytokines in a rapid and replication-independent manner, the activation of 
cytokine expression is likely mediated by binding of EIAV17 to equine macrophage 
receptor(s).   
 v
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CHAPTER I 
 
INTRODUCTION 
 
Overview 
 Equine infectious anemia virus (EIAV) belongs to the lentivirus genus in the 
Retroviridae family.  EIAV exclusively infects and replicates in the macrophages of 
equids, including horses, ponies, donkeys and mules (Ishitani, 1970).  The predominant 
route of EIAV transmission is the interrupted feeding of large arthropods on infected 
animals (Issel and Foil, 1984).  Other transmission routes include transfusion of infected 
blood and, in rare cases, cross-placental infection of the fetus (Coggins, 1984).  EIAV 
causes acute and chronic disease, but most infected horses ultimately mount an immune 
response that effectively control viral replication and become inapparent carriers.  
Although the inapparent carriers are clinically normal, they remain infected for life and 
are important reservoirs of EIAV in nature (Montelaro et al., 1993).  Transmission from 
inapparent carriers is demonstrated in both experimental and natural conditions 
(Coggins, 1984).   
 Since the implementation of mandatory quarantine and surveillance of 
seropositive horses using an agar gel immunodiffusion (AGID) test (Coggins et al., 
1972), spread of EIAV has been controlled in the US.  However, all attempts to develop 
inactivated whole-virus and subunit vaccines have been unsuccessful, and EIAV remains 
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an important equid disease with major economic impacts worldwide (Costa et al., 1997; 
Issel et al., 1992; Wang et al., 1994).   
 
The Virion 
Electron microscopy reveals that the EIAV virion ranges from round to ellipsoidal in 
shape and measures 95-125 nm in diameter.  A double-layered envelope surrounds a 
condensed capsid core that is either conical (75-95 nm in length) or tubular (up to125 nm 
in length) in shape.  The outer layer of the envelope is studded with 10-12nm long 
projections (Weiland et al., 1977; Gonda et al., 1978).  The capsid core contains a 
diploid genome which consists of 2 single-stranded positive RNA held together by base-
pairing and a genome-associated tRNALys that serves as a primer for the synthesis of the 
negative strand viral DNA (Cheevers et al., 1977; Charman et al., 1976; Stephens et al., 
1986).   
 
Genomic Organization 
 Both ends of the EIAV proviral DNA terminate with the long terminal repeat 
(LTR) comprised of U3 (unique 3’sequence), R (redundant sequence) and U5, which 
contain critical transcription regulatory sequences (Fig. 1A) (Maury, 1998; Derse et al., 
1987).  The 5’ LTR is immediately followed by the tRNALys primer binding site (PBS) 
(Derse et al., 1987).  As in all lentiviruses, EIAV has gag, pol and env genes that encode 
the major structural proteins and enzymes (Fig. 1A) (Stephens et al., 1986).  In addition, 
EIAV possesses 3 small open reading frames (ORF), S1, S2 and S3, encoding accessor 
S2U3 U5
5’ LTR gag pol
env
S1
S3
R U3 U5
3’ LTR
R
A.
B. AAA
gag pol S1 S2 env S3U5 U3 R
440
R
5116 721655185257 5418
AAAC.
AAAD.
AAAE.
AAAF.
Fig. 1. Illustrations of EIAV genomic organization and mRNA transcripts.  A schematic of full-length proviral EIAV 
is illustrated in A, with the long terminal repeats and open reading frames shown as open boxes.  The principal 
mRNA transcripts of EIAV are represented as solid lines in B-F.  Genomic positions of the splice sites are indicated 
by arrows above the solid line in B, numbered according to the previously published EIAV provirus genomic 
sequence (1,2).  Minor and alternative transcripts are not included.  Transcript B represents the 8.0kb genomic RNA 
that encodes Gag and Pol proteins.  Transcript C represents the singly spliced polycistronic mRNA that encodes for 
Env, Tat and S2.  Transcripts D and E represent the multiply spliced transcripts that encode Tat and Rev. Transcript F 
represents the mRNA that encodes the Ttm protein.  Illustrations are not drawn to scale.
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proteins.  S1 is located in the pol-env intergenic region.  S2 begins in the pol-env 
intergenic region and overlaps with env in a different reading frame.  S3 is completely 
contained within env as an alternative reading frame (Rushlow et al., 1986).  With 
approximately 8.0 kb, the EIAV genome is the smallest among the lentiviruses because 
of its short LTR and pol-env regions and small number of accessory proteins. 
 Transcription of EIAV proviral DNA produces three types of mRNAs, unspliced 
(full-length), singly-spliced and multiply-spliced (Fig. 1B to F).  Synthesis of the 8.0-
8.2kb full-length mRNA starts at the 5’ U3-R junction of the provirus and terminates in 
the 3’ R region (Fig. 1B).  This transcript serves as the genomic RNA as well as drives 
the translation of the Gag and Pol proteins.  All spliced EIAV transcripts contain a 
common leader sequence derived from R, U5 and the region preceding gag (Stephens et 
al., 1990; Maury, 1998).  The 3.5-4.0kb singly-spliced transcript is a polycistronic 
mRNA that encodes for Env, Tat (S1) and S2 (Fig. 1C) (Schiltz et al., 1992).  A number 
of different multiply spliced transcripts have been identified, ranging from 1.2 to 1.5kb 
in size (Fig. 1D and E).  These transcripts encode for the regulatory proteins Tat and Rev 
(S3) (Stephens et al., 1990; Carroll and Derse, 1993).  Beisel et al. reported a small 
transcript that encodes a fused protein (Ttm) consisting of the Tat leader and the C-
terminus of the transmembrane (TM) glycoprotein (Fig. 1F) (Beisel et al., 1993).  The 
function of Ttm is unknown but is likely to contribute to the cytopathic effects of EIAV 
infection since it contains the putative membrane-destabilizing cytoplasmic TM 
(Venable et al., 1989).  A unique feature of EIAV transcription is that while the multiply 
spliced mRNAs are readily detectable in liver tissues of EIAV-infected horses and in 
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EIAV-infected non-equine cell lines, they are rarely detected in infected equine cell lines 
(Beisel et al., 1993; Rasty et al., 1990; Schiltz et al., 1992; Stephens et al., 1990).  
Despite the rarity of the multiply spliced mRNAs, Tat activity can be measured in 
infected equine cell lines (Rasty et al., 1990).   
 
Gag Proteins 
 The gag gene encodes structural proteins p15 (matrix, MA), p26 (capsid, CA), 
p11 (nucleocapsid, NC) and p9.  These proteins are arranged as a 55kDa precursor, p15-
p26-*-p11-p9, where the asterisk represents a pentapeptide (Henderson et al., 1987).  
The precursor is cleaved during or after budding of EIAV to yield the 4 individual Gag 
proteins (Henderson et al., 1987).   
 MA of retroviruses targets Gag to the plasma membrane during viral assembly 
and remains associated with the inner membrane leaflet of mature virions to form the 
outer shell.  Membrane binding properties of EIAV MA have been demonstrated by 
fluorescence and biochemical methods (Provitera et al., 2000).  However, EIAV MA 
lacks the N-terminal myristoylation signal and cluster of positively charged residues that 
human immunodeficiency virus (HIV)-1 MA utilizes to interact with anionic membranes 
(Freed, 1998).  The recently resolved crystal structure suggests that EIAV MA may 
interface with membranes through an amphipathic helical structure (Hatanaka et al., 
2002).  Despite the lack of sequence homology, EIAV MA crystal structure displays 
overall similarity with those of HIV-1 and simian immunodeficiency virus (SIV) MA.  
However, EIAV MA forms dimers instead of trimers like HIV-1 and SIV MA (Hatanaka 
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et al., 2002).  In HIV-1, MA also plays important roles in facilitating transport of the 
viral genome into the nucleus. The nuclear localization signal found in HIV-1 MA is 
absent in EIAV MA (Hatanaka et al., 2002).  However, since nuclear targeting of HIV-1 
DNA is dependent on MA serine phosphorylation, the early observation that EIAV MA 
serine and threonine residues are variably phosphorylated may indicate its involvement 
in nuclear translocation (Montelaro et al., 1982; Hatanaka et al., 2002).   
 CA of EIAV forms the core structure that contains the viral genome, 
nucleocapsid protein and enzymes (Roberts and Oroszlan, 1989).  Recombinant EIAV 
CA forms cubic and hexagonal crystal structures.  Crystallography of the protein reveals 
a novel antiparallel four-helix bundle motif that provides the interface for N-terminal 
domain dimerization (Jin et al., 1999).  Assembly of mature EIAV capsid is believed to 
depend on this N-terminal interaction in conjunction with the C-terminal domain 
dimerization analogous to that seen in HIV-1 CA (Jin et al., 1999).  It is not clear 
whether EIAV CA possesses other functions that have been associated with HIV-1 CA 
such as cyclophilin binding (Freed, 1998).  CA is the major protein used in commercial 
EIA diagnostic tests, including the Coggins’ AGID test, because it is abundantly 
produced and antigenically conserved (Sellon et al., 1994).   
 The p11 Gag protein is the NC protein which binds to the viral genome to form 
the ribonucleoprotein complex in the EIAV core (Montelaro et al., 1982).  EIAV NC 
contains two zinc finger motifs, a highly conserved feature among retroviruses (Stephens 
et al., 1986).  In HIV-1 NC, the zinc finger motifs are important for binding RNA, 
specific encapsidation of full-length genomic RNA and RNA dimerization and stability 
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(Freed, 1998).  Topoisomerase I activity is localized to an 11kDa protein isolated from 
the EIAV core.  This protein is proposed to be the NC protein based on its cross-
reactivity with anti-NC antibody, although the identity needs to be confirmed with more 
definitive evidence such as amino acid sequencing (Matsrafi et al., 1996).  
 Only EIAV and the primate lentiviruses (HIV, SIV) encode an additional protein 
following the NC at the C-terminus of Gag (known as p9 in EIAV, p6 in HIV and SIV).  
EIAV p9 is important for viral budding and indispensable for viral infectivity (Chen et 
al., 2001; Li et al., 2002; Puffer et al., 1997; Puffer et al., 1998).  The budding function 
of p9 is localized to the L domain of the protein containing a YPDL motif (Puffer et al., 
1997).  Although the p9 L domain is not absolutely required for viral budding, deletion 
of the YPDL motif or truncation of 21 or more C terminal amino acids of p9 produces 
noninfectious EIAV (Chen et al., 2001; Li et al., 2002).  The L domain is also shown to 
interact in vitro with the cellular AP-2 complex, an element of the clathrin-dependent 
endocytic pathway, which suggests host cell proteins and/or pathways are utilized to 
perform L domain-mediated functions (Li et al., 2002). 
 
Pol Proteins 
 The pol gene overlaps with the gag gene by 241 bp.  A ribosomal frameshift is 
required for translation of pol gene from the 8.0 kb gag - pol transcript.  The Pol protein 
is the precursor for 4 viral enzymes: the protease (PR), reverse transcriptase (RT), 
dUTPase, and integrase (IN) (Montelaro et al., 1993). 
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PR is a homodimeric protein that is responsible for cleaving the Gag and Pol 
precursors during the late phases of retroviral replication.  EIAV PR cleaves Gag and Pol 
at specific sites, most of which contain either an aromatic-proline or a hydrophobic-
hydrophobic junction (Tozser et al., 1993).  EIAV PR also cleaves TM into 
transmembrane and cytoplasmic proteins, as well as the RNase H domain of the RT to 
yield the 55kDa RT subunit (Tozser et al., 1993).  Interestingly, EIAV PR effectively 
processes substrates of HIV-1 origin but is resistant to almost all potent inhibitors of 
HIV-1 PR, thus behaves as a drug-resistant mutant of HIV-1 PR (Powell et al., 1996). 
This property of EIAV PR has led to interests in biochemical and crystallographic 
characterizations of the interactions between EIAV PR and inhibitors or substrates, 
which are potentially useful for design of future anti-AIDS (acquired immune-
difficiency syndrome) drugs (Powell et al., 1996).   
RT of all retroviruses possess RNA- and DNA-dependent DNA polymerase and 
ribonuclease (RNase) H activities (Coffin, 1996). The RNA-dependent DNA 
polymerization (reverse transcription) is initiated by a tRNALys base-paired at the PBS of 
the RNA genome.  RNA in the resultant RNA:DNA hybrid is then degraded by the 
RNase H activity of RT.  Finally, the DNA-dependant DNA polymerase function of RT 
synthesizes the second DNA strand.  EIAV RT shares remarkable sequence similarity 
with other lentiviruses, especially HIV-1 and HIV-2 (Wohrl et al., 1994).  EIAV RT is a 
heterodimer consisting of 66kDa and 51kDa subunits, with the latter lacking the C-
terminal RNaseH domain.  Studies of recombinant EIAV RT reveal that homodimers of 
the 51kDa subunit polymerize in an abortive mode which generates short DNA products, 
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indicating that the RNase H domain is also essential for template processivity of RT 
(Wohrl et al., 1994).  Like other lentiviral RT's, EIAV RT lacks a 3'-5' exonuclease 
activity (Bakhanashvili and Hizi, 1993).  This property of RT leads to high rates of 
nucleotide misinsertions and efficient mispair extensions during replication of the viral 
genome and contributes to the high degree of genetic variation seen in EIAV. 
 dUTPase hydrolyzes dUTP to dUMP, reducing the concentration of dUTP and 
providing substrate for biosynthesis of dTTP (Dauter et al., 1999).  The overall effect is 
maintaining a low dUTP:dTTP ratio and hence reducing the chances of mis-
incorporation of dUTP into DNA.  EIAV dUTPase is required for efficient viral 
replication in the non-dividing equine macrophages which express low levels of cellular 
dUTPase but is dispensable in permissive cell lines where cellular dUTPase is 
abundantly expressed (Shao et al., 1997).  Crystal structural analyses reveal that the 
active EIAV dUTPase is a homotrimer (Dauter et al., 1999).  The depressions created at 
the interfaces of the subunits provide the active center and the binding site for a divalent 
cation that is required for catalysis.  
 Integration of viral DNA into the host genome is a crucial feature of retrovirus 
replication.  Retrovirus IN cleaves the RT-generated double-strand viral DNA at 
conserved CA dinucleotides near the 3’ end of each strand (Coffin, 1996).  The 3’OH 
created is utilized by IN to attack phosphate bonds of the host genomic DNA during the 
strand transfer reaction.  Purified EIAV IN displays 3’ processing and DNA strand-
transfer activities and seems to function like other retroviral INs (Engelman, 1996).  
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EIAV IN bears particular similarity with HIV-1 IN in that they both use water instead of 
viral DNA 3’OH as the nucleophile in the Mn2+-dependent 3’ cleavage reaction. 
 
Env Proteins 
 The EIAV Env protein is translated from a singly-spliced, polycistronic mRNA 
as a 135kDa precursor (Schiltz et al., 1992; Rice et al., 1990).  In the synthesis of 
retrovirus Env proteins, the Env precursor is cotranslationally translocated to the rough 
endoplasmic reticulum (ER) where the hydrophobic signal peptide is cleaved (Coffin, 
1996).  However, EIAV Env processing is unique.  N-terminal protein sequencing has 
shown that only 6 residues are cleaved from the EIAV Env N-terminus instead of the 
predicted 15 amino acid signal peptide (Ball et al., 1988).  Retroviral Env precursors 
undergo oligomerization and glycosylation in the ER (Coffin, 1996).  EIAV Env 
contains 18 potential glycosylation sites, 13 in the SU (surface unit) region and 5 in the 
TM region (Kawakami et al., 1987).  The precursor Env is then transported to the Golgi 
where it is cleaved by cellular enzymes into SU and TM subunits (Coffin, 1996).  
Finally, EIAV TM is further cleaved by the viral protease in the virion to yield gp32 and 
p20 (Rice et al., 1990).  
 
SU 
Early studies establish that each of the recurring episodes of disease during the 
chronic phase of EIA is associated with an emergence of new EIAV variants that escape 
the surveillance of the established immune response (Montelaro et al., 1984) (Fig. 2).   
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Fig. 2.  Schematic representation of EIA clinical course and the kinetics of 
immune response.  The chart illustrates the temporal relationship between 
the recurring episodes of disease, the viremia of antigenically distinct 
EIAV variants, and the emergence of variant-specific immune response.  
The x-axis represent days post-infection.  The left and right y-axes 
represent temperatures (oC) and platelet counts (103/ml of whole blood) of 
infected horses, respectively. (Illustration from S. L. Payne; Issel and 
Coggins, 1979;  Payne et al., 1998)
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Immunologic and biochemical assays show that the variations of EIAV are 
predominantly localized to the Env protein, in particular SU (Salinovich et al., 1986; 
Montelaro et al., 1984).  Since EIAV SU is the major target of neutralizing antibodies, 
the appearance of escape mutants is attributed to the rapid antigenic alterations within 
SU that enable new EIAV variants to evade deactivation by pre-existing neutralizing 
antibodies (O'Rourke et al., 1988; Salinovich et al., 1986; Rwambo et al., 1990).  Indeed, 
the epitopes of all EIAV neutralizing monoclonal antibodies (MAbs) are localized to 
variable regions of SU (Hussain et al., 1988).  Based on nucleotide sequence analyses of 
EIAV isolates from sequential disease episodes, 2 conserved and 1 variable domains 
within the EIAV SU are apparent (Payne et al., 1987).  The conserved domains are 
located at the N-terminus (CN, amino acids 1 to 137) and the C-terminus (CC, amino 
acids 360 to 445).  The variable domain (V) lies between CN and CC and contains a 
hypervariable domain (VH, amino acids 300-335).  By peptide mapping, Ball et al. 
localize 3 neutralizing epitopes within the V domain (Ball et al., 1992).  A very short 
segment of the V domain (amino acids 174-207), termed the principal neutralizing 
domain (PND), contains 2 of the 3 neutralizing epitopes and reacts with 75% of the 
EIAV-infected horse sera tested.  These results reinforce the concept that neutralizing 
antibodies are directed towards a region of SU that is highly variable.  Amino acid 
alterations within this SU region give rise to new EIAV variants that evade the 
established humoral immune response and cause recurring disease episodes.   
The principal function of retroviral SU proteins is to bind cellular receptors 
during attachment of the virus to the target cells (Gallaher et al., 1995).  Genetic 
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analyses show that there are substantial differences in the VH and PND of SU between 
macrophage-tropic EIAV field strains and EIAV strains adapted to grow in fibroblastic 
cell lines (Perry et al., 1992; Lichtenstein et al., 1996).  However, insertion of SU from a 
macrophage-tropic EIAV into the cell line-adapted EIAV clone does not restrict the 
growth of EIAV in cell lines (Perry et al., 1992).  These results suggest that VH and PND 
are not directly involved in receptor interaction.  This is similar to HIV-1 SU, whereby 
the variable regions do not directly interact with CD4 but form physical “shields” to 
protect the CD4-binding constant regions from neutralizing antibodies (Coffin, 1996).  
Such arrangements allow mutations of the neutralizing epitopes in the variable regions 
without affecting receptor binding.  To date, the receptor for EIAV SU has not been 
identified on the surface of macrophages or fibroblastic cells.   
A structural model of EIAV SU has been generated based on computer 
algorithms and comparison to structures of other lentiviral SU proteins (Ball, 1990; 
Gallaher et al., 1995).  In this model, EIAV SU is an overall globular molecule with 
randomly distributed positive and negative charges.  The proposed model reveals a 
number of structural features homologous to HIV-1 or other retroviral SU proteins 
within each region.  Functions are assigned to these structures based on the known 
functions of HIV-1 SU (Ball, 1990; Montelaro et al., 1993; Ball, 1990).  The CN domain 
contains 3 structural properties that are common among retroviral SU proteins: (1) a 
predicted amphipathic α-helix that is believed to be highly immunogenic; (2) cysteine 
residues that are potentially involved in disulphide linkages; and (3) a region consisting 
of strong turn potential followed by N-linked glycosylation sites and an α-helix (Ball, 
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1990).  This model predicts that PND is at the most exposed region of the V domain and 
projects out from the surface of SU (Ball et al., 1992).  Based on similarities in antigenic 
and structural properties, the PND is proposed to be functionally analogous to the V3 
loop of HIV-1, which participates in co-receptor utilization and cell tropism.  In addition 
to the PND, the VH domain is also predicted to protrude from the SU surface since this 
region contains 2 cysteine residues that may contribute to the formation of a loop 
structure (Ball, 1990; Ball et al., 1992).  The protrusion of the PND and the VH domain 
may account for their high antigenicity and variability.  In the CC region, the domain 
adjacent to the cleavage site is predicted to form a series of amphipathic helices that may 
facilitate oligomerization of SU (Ball et al., 1992).   
 
TM 
 Like SU, the functions of TM in EIAV replication have not been demonstrated 
directly.  It is assumed that the EIAV TM is functionally homologous to TM of other 
retroviruses, which mediate the fusion of viral and cellular membranes upon receptor 
binding to allow release of the viral core into the cytoplasm.  A putative structure of 
EIAV TM has been predicted using computer algorithms and is largely modeled after the 
known structure of the influenza TM (HA2) (Ball, 1990; Gallaher et al., 1989).  As in the 
model of SU structure, various functions are assigned to the structural features of EIAV 
TM based on similarities to the HIV-1 TM and the influenza HA2.  This model predicts 
EIAV TM has a fibrous structure with an overall hairpin-like conformation.  The N 
terminus of TM contains a hydrophobic core and is believed to constitute the fusion 
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peptide, which is inserted into the cellular membrane during membrane fusion.  
Downstream to the fusion peptide is an extended amphipathic helical structure that gives 
the protein its fibrous character and facilitates Env oligomerization.  The apex of the TM 
contains 2 vicinal cysteine residues believed to form a disulphide linkage that maintains 
the hairpin conformation.  Near the C terminus, a hydrophobic segment forms the 
proposed transmembrane domain responsible for anchoring the TM protein to the viral 
envelope (Ball, 1990; Gallaher et al., 1989).  The C terminus of TM is cytoplasmic.  The 
sequence of this region reveals a potential to form membrane-spanning channels that 
may have cytopathic effects (Venable et al., 1989). 
 While variations of TM are evident among EIAV isolates, they are more 
conserved compared to SU (Payne et al., 1987; Leroux et al., 1997).  Amino acids are 
most highly conserved within the proposed fusion peptide and transmembrane domain 
(Payne et al., 1987).  The fusion peptide and the apex of the hairpin structure represent 2 
immunodominant regions that react with a high percentage of immune horse sera 
(Chong et al., 1991).  The epitopes within the apex region are highly conserved but do 
not appear to be neutralizing (Chong et al., 1991; Hussain et al., 1987).   
 
Accessory Proteins 
The S1 ORF encodes the EIAV Tat protein (Stephens et al., 1990).  Translation of Tat 
utilizes an unusual CTG initiator codon in the leader sequence located in the LTR.  
Therefore, 29 amino acids derived from the leader sequence are fused to the N-terminus 
of Tat but are dispensable for Tat activity.  Tat activity is required for productive 
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expression of EIAV proteins from full-length provirus (Carvalho and Derse, 1991; 
Maury, 1998).  Enhancement of EIAV expression from the LTR by Tat is through an 
interaction with TAR (Tat response element), a stem-loop structure in the nascent 
transcript formed by the first 24 ntds of the LTR-R.  An essential property of EIAV Tat 
is its ability to bind equine cyclin T1, a component of the positive transcription 
elongation factor b (P-TEFb), and recruit P-TEFb to TAR (Bieniasz et al., 1999).  P-
TEFb enhances elongation efficiency of RNA polymerase II and hence promotes viral 
gene expression.  Involvement of additional cellular proteins in Tat activation has been 
suggested but their identities and roles are unknown (Sune et al., 2000). 
 The S2 ORF encodes a 7kDa product, termed S2 protein, of undetermined 
function.  S2 seems to be dispensable for EIAV replication in vitro as EIAV that lacks 
S2 replicates as efficiently as S2-positive EIAV in primary equine macrophages and an 
equine dermal cell line (Li et al., 1998).  In contrast, in vivo data show that EIAV 
lacking S2 causes less severe thrombocytopenia and displays lower levels of viral 
replication in ponies compared to S2-positive EIAV (Li et al., 2000).  S2 contains 
distinct functional motifs including a nuclear localization signal, a nucleoporin motif, 
and an SH3-binding motif (Yoon et al., 2000).  The relative genomic location of S2 and 
its high serine-threonine content spur the concept that S2 is functionally similar to HIV-1 
Vpu, an accessory protein that facilitates assembly and release of virions (Li et al., 
1998).  Supporting this concept, a study demonstrates that, like Vpu, S2 localizes to 
cytoplasm and associates with subcellular structures (Yoon et al., 2000).  In the same 
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study, S2-Gag precursor interaction is shown by co-immunoprecipitation, which 
suggests participation of S2 in viral assembly. 
 EIAV Rev is encoded by at least three different multiply-spliced transcripts 
(Rosin-Arbesfeld et al., 1993).  Two of the transcripts contain 4 exons and generate 
products consisting of the N-terminus of Env fused to Rev.  The third transcript produces 
a form of Rev that lacks the Env N-terminus.  EIAV Rev regulates relative abundance of 
spliced and unspliced viral RNA in the cytoplasm via a pathway homologous to that of 
HIV-1 Rev (Belshan et al., 2000).  Rev binds viral RNA at the Rev response element 
(RRE) and shuttles full-length and singly spliced viral RNA out of the nucleus through 
interactions with the cellular nuclear export protein CRM1 (chromosomal region 
maintenance) (Otero et al., 1998).  In addition to mediating RNA export, EIAV Rev also 
participates in regulating alternative splicing.  Binding of Rev to an exon splicing 
enhancer (ESE) motif in its own transcript prevents the inclusion of one of the exons in 
the multiply-spliced mRNA (Belshan et al., 2000). 
 
EIAV Cell Tropism 
Macrophages in spleen, liver, lymph node, kidney, lung and adrenal gland have 
been identified as the predominant sites of active EIAV replication based on the analyses 
of tissues from acutely infected EIA horses by in situ hybridization specific for EIAV 
gag (Sellon et al., 1992).  Although EIAV DNA is detectable in PBMC of these horses, 
viral RNA is absent in these cells, suggesting that undifferentiated monocytes are 
susceptible to EIAV infection but do not support productive viral replication (Sellon et 
 
 
18
al., 1992).  Tissue macrophages also serve as cellular reservoirs of EIAV during 
subclinical infection (Sellon et al., 1992; Oaks et al., 1998).  In addition, spleen and bone 
marrow macrophages are shown to be sources of restricted viral transcription in 
subclinically infected horses, which may be important for viral persistence (Sellon et al., 
1992; Oaks et al., 1998).  Endothelial cells are the only other cell type that may support 
productive EIAV replication in acutely infected horses (Oaks et al., 1999).  EIAV is also 
detected in endothelial cell culture isolated from a long term EIAV carrier (Maury et al., 
1998).   
 One of the unique features of EIAV cell tropism is its linkage to the in vivo 
virulence of the virus.  In cell culture, virulent strains or field isolates of EIAV replicate 
only in equine macrophages and are very restricted for replication in cell lines 
(Carpenter and Chesebro, 1989).  EIAV can be adapted to growth in equine kidney cells 
or equine, canine or feline fibroblast cell lines through repeated passages (Maury, 1998).  
However, the cell line-adapted strains are avirulent in vivo (Carpenter and Chesebro, 
1989; Maury, 1998).  Recently, a canine macrophage-like cell line has been shown to 
support replication of both macrophage- and fibroblast-tropic EIAV strain (Hines and 
Maury, 2001).  However, this cell line fails to support the growth of the highly virulent 
Wyoming wild type EIAV (EIAVWyo). 
 Despite the importance of SU in cell tropism of many retroviruses, it does not 
seem to be a determinant of EIAV tropism (Perry et al., 1992).  Substitution of SU 
sequences from a fibroblast-tropic proviral clone of EIAV with those derived from the 
EIAVWyo, which is unable to replicate in fibroblasts, does not affect cell tropism.  On the 
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other hand, the enhancer region (ntds -111 to –31) contained within the U3 domain of 
EIAV LTR appears to play major roles in EIAV cell tropism.  The enhancer region is 
highly variable and contains binding sites for cellular transcription factors (Maury, 
1998).  LTR transcription in macrophages and fibroblastic cell lines involves distinct 
repertoires of transcription factors.  In fibroblast, LTR transcription is highly sensitive to 
point mutations in the PEA-1, octamer, and CRE binding motifs.  In primary equine 
macrophages, however, the ets binding sites are critical for LTR transcription and are 
bound by the myeloid/B cell-specific transcription factor PU.1.  Furthermore, changing 
one of the GTTCC ets motifs within the EIAVWyo-derived LTR to a CTTCC ets (single 
ntd substitution), as commonly found in the LTR of fibroblast-adapted EIAV, 
dramatically increases its transcription in fibroblasts (Payne et al., 1999).   
 The relationship between in vitro cell tropism and in vivo virulence of EIAV is 
still not understood.  Although the alteration in the transcription factor motifs may affect 
viral replication and hence the virulence of EIAV in vivo, it has been shown that the 
sequence of virulent EIAV 3’ LTR alone does not impart virulence (Lichtenstein et al., 
1996; Cook et al., 1998).  EIAV virulence appears to involve combinations of multiple 
determinants as discussed below.   
 
Lentiviral Infections and Macrophage Cytokines 
Aside from EIAV, macrophages are also the major targets of infection for all 
lentiviruses including caprine arthritis encephalitis virus (CAEV), feline 
immunodeficiency virus (FIV), maedi-visna virus (MVV), HIV and SIV (Gendelman et 
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al., 1986; Narayan et al., 1983; Meltzer et al., 1990; English et al., 1993; Mori et al., 
1992; Onuma et al., 1992).  However, with the exception of HIV, studies of cytokines 
associated with lentiviruses are scant, probably due to the lack of commercially available 
cytokine reagents for these animal species (Bornemann et al., 1997).  Table 1  
summarizes the results of select published data that show alteration of macrophage 
cytokines associated with infection by lentiviruses.  Together, these results suggest that 
dysregulation of cytokine expression is a common outcome of lentiviral infection of 
macrophages.   
To date, there are only 5 studies that report analysis of cytokine activities 
associated with EIAV infection.  Costa et al. report detection of tumor necrosis factor 
(TNF)-α in plasma of EIAV-infected ponies and shows a positive correlation between 
plasma TNF-α concentration, severity of symptoms and strain virulence (Costa et al., 
1997).  TNF-α is again shown to be elevated along with transforming growth factor 
(TGF)-β and interferon (IFN)-α in serum of ponies infected with EIAVWSU5 (Tornquist 
et al., 1997).  The same study detects increased levels of TNF-α, TGF-β and IFN-α in 
bone marrow biopsies of infected animals.  Sera from ponies experimentally infected 
with EIAVWyo show increased interleukin (IL)-6 activity, which positively correlates 
with EIAV replication (Sellon et al., 1999).  In the only study that specifically measures 
macrophage-secreted cytokines, infection of bone marrow-derived macrophages 
(BMDM) with EIAVWSU5 in vitro increases IL-6 but not TNF-α activity in the culture 
supernatant (Swardson et al., 1997).  A recent study investigated the expression of IFN-γ 
and IL-4 in PBMC of EIAV carrier horses (Fraser et al., 2002).  This study shows that  
Table 1 
Dysregulation of macrophage cytokines and chemokines by lentiviruses 
  HIV-1  SIV FIV MVV CAEV EIAV 
  Effectsa References  Effects References Effects References Effects References Effects References Effects References 
GM-CSF  ↑ Bornemann et al., 
1996 
     ↔ Ebrahimi et al., 
2000 
↑*    
IFN-α  ↑ Bornemann et al., 1996            
IFN-γ  ↑↔ Cicala et al., 2002; Bornemann et al., 
1996 
   ↑ Ritchey et al., 
2001 
      
IL-1β  ↑ Cicala et al., 2002  ↑↔* Sopper et al., 1996; Horvath, 
et al., 1991
  ↔ Ebrahimi et al., 
2000 
↓* Lechner et al., 
1997 
  
IL-4  ↓ Bornemann et al., 
1996 
           
IL-6  ↑ Bornemann et al., 
1996 
 ↑↔* Sopper et al., 
1996; Horvath et 
al., 1991
↑ Ritchey et al., 
2001 
↑ Ebrahimi et al., 
2000 
↓* Lechner et al., 
1997 
↑ Swardson et al., 
1997 
IL-8  ↑ Roux et al., 2000  ↑↔* Sopper et al., 
1996; Horvath et 
al., 1991
  ↑ Legastelois et 
al., 1998 
↑ Lechner et al., 
1997 
  
IL-10  ↑↓ Bornemann et al., 
1996 
   ↑ Ritchey et al., 
2001
↔ Ebrahimi et al., 
2000 
    
IL-12  ↑↓ Bornemann et al., 
1996; Fantuzzi et al., 
1996 
     ↔ Ebrahimi et al., 
2000 
↓* Lechner et al., 
1997 
  
IP-10  ↑ Cicala et al., 2002            
MIP-1α  ↑ Choe et al., 2001        ↑ Lechner et al., 1997   
MIP-1β  ↑ Choe et al., 2001            
NAP2  ↑ Cicala et al., 2002            
RANTES  ↑ Choe et al., 2001            
TGF-β  ↑ Bornemann et al., 1996      ↔ Ebrahimi et al., 2000     
TNF-α  ↑ Cicala et al., 2002  ↑↔* Sopper et al., 1996; Horvath et 
al., 1991
↑ Ritchey et al., 
2001 
↑ Ebrahimi et al., 
2000 
↓* Lechner et al., 
1997 
↔ Swardson et al., 
1997 
a ↑, increase; ↓, decrease; ↔, no change.   
* Viral infection affects LPS-stimulated cytokine expression. 
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peptides corresponding to Gag epitopes selectively stimulate IFN-γ, whereas the peptide 
corresponding to a Pol epitope stimulates both IFN-γ and IL-4.   
In most lentivirus cytokine studies, in vivo and/or in vitro infection of 
macrophages result in alterations of the constitutive cytokines levels.  For example, both 
in vitro and in vivo FIV infection causes an increase in the constitutive expression of 
TNF-α and IL-6 in cat alveolar macrophages (Ritchey et al., 2001).  Similarly, increase 
of IL-8 mRNA expression is detected in sheep alveolar macrophages infected with MVV 
in vitro and isolated from naturally infected sheep (Legastelois et al., 1997; Legastelois 
et al., 1998).   
Alternatively, lentiviral infection affects the capability of macrophages to 
produce cytokines upon exposure to exogenous stimulation.  Infection of caprine 
macrophages with CAEV, for instance, does not affect the constitutive expression of 
IL12 p40 and IL-6 but rather suppresses the lipopolysaccharide (LPS)-stimulated 
expression of these genes (Lechner et al., 1997).  In contrast, microglia (resident tissue 
macrophages of the brain) isolated from SIV-infected Rhesus monkey display a 
tendency to produce higher levels of inflammatory cytokines when stimulated with LPS 
(Sopper et al., 1996).   
Discrepant results are often reported in the studies of cytokine alteration in 
lentivirus-infected macrophages. Effects of a given lentivirus on a cytokine may range 
from upregulation, no change, to inhibition (Table 1).  The factors that contribute to 
these variations include, among others, origins of macrophages, in vivo versus in vitro 
infection of macrophages, and timing and methodology of cytokine analysis.  For 
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example, increase in constitutive TNF-α production is detected in microglia cells of 
SIVmac251-infected monkeys but is absent in peripheral and alveolar macrophages 
isolated from animals infected with the same strain of SIV (Sopper et al., 1996; Horvath 
et al., 1991).  In another example, macrophages exposed to HIV-1 SU (gp120) produce 
IL-12 when primed with IFN-γ.  However, IL-12 production is impaired in macrophages 
of HIV-1-infected patients (Fantuzzi et al., 1996).  These seemingly paradoxical findings 
are potentially explained by the ability of HIV-1 to induce IL-10 production, which 
downregulates IL-12 production by macrophages (Fantuzzi et al., 1996).  These results 
emphasize the complexity of cytokine regulation and the necessity to consider the 
clinical significance of lentivirus-induced cytokine dysregulation in appropriate 
physiological contexts.   
With the exception of HIV-1, the molecular mechanisms by which lentivirus 
regulate expression of cytokines in macrophages are largely unknown.  HIV-1 gp120 
induces cytokines such as IL-1β, IL-6, IL-10, IFN-γ, TNF-α and a number of β 
chemokines by binding to the CD4 molecules on the surface of macrophages (Chirmule 
and Pahwa, 1996; Choe et al., 2001).  In addition to serving as a receptor for virus entry, 
CD4 is shown to trigger signal transduction pathways that modulate expression of over 
300 genes in monocyte-derived macrophages upon binding to gp120 (Cicala et al., 
2002).  It is believed some of these signaling events result in activation of transcription 
factors such as NFAT which are closely associated with regulation of cytokine 
expression (Cicala et al., 2002).  In addition to gp120, exposure of macrophages to HIV-
1 Vpr protein also results in upregulation of IL-8, presumably through the activation of 
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transcription factors NF-IL-6 and NF-kB (Roux et al., 2000).  Finally, the HIV-1 Tat 
protein, which directly participates in transactivation of gene transcription, is shown to 
enhance the transcription of TGF-β1, TNF-α and IL-6 (Zauli et al., 1992; Lechner et al., 
1997).  This mechanism may also be employed by CAEV to regulate cytokine 
expression in macrophages (Lechner et al., 1997).  Given the similarity between 
lentiviruses, these mechanisms may serve as paradigms for understanding mechanisms 
involved in cytokine induction by EIAV.   
 
Roles of Macrophage Cytokines in Lentivirus Pathogenesis 
Understanding the alteration of macrophage cytokines associated with lentiviral 
infection is important as cytokines play central roles in lentiviral pathogenesis.  
Cytokines produced by macrophages affect disease outcome by directly causing 
symptoms, regulating lentivirus replication, and modulating both innate and acquired 
immune responses to lentiviral infection.  Unsurprisingly, the pathogenic roles of 
cytokines have been most comprehensively explored in HIV-1 infection, which will 
serve as a model for the following discussions.   
The direct pathological roles of macrophage cytokines are well-established in the 
development of neurological disorders commonly associated with late stages of HIV 
infection (Xiong et al., 1999).  Inflammatory cytokines including IL-1 and TNF-α are 
produced by HIV-1-infected brain macrophages and microglia.  These cytokines 
contribute to degeneration of neuronal functions by both their inherent neurotoxic 
properties and their ability to induce synthesis of other neurotoxins such as oxygen free 
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radicals and prostaglandins (Tan and Guiloff, 1998).  Many of the macrophage-secreted 
cytokines and chemokines, such as TGF-β, TNF-α, IL-6, and macrophage inflammatory 
protein (MIP)-1α, are known as important regulators of the hematopoietic process 
(Croker and Milon, 1992).  Hence, production of macrophage cytokines by HIV-1-
infection is believed to have major impacts on development of HIV-1-associated 
hematological disorders such as anemia and thrombocytopenia (Zauli et al., 1992; 
Means, , 1997).  T cell depletion associated with HIV-1 infection is due to both the death 
of infected T cells and increase apoptosis of uninfected T cells (Badley et al., 1997).  
Apoptosis of T cells from HIV-infected individuals is induced by TNF-α in vitro 
(Badley et al., 1997).   
The feature of cytokines in relation to HIV-1 that has attracted the most attention 
is their ability to regulate HIV-1 replication.  Macrophages are a major source of many 
cytokines that enhance HIV expression in infected cells, including IL-1α, IL-1β, IL-6, 
IL-12, macrophage colony-stimulating factor (M-CSF), granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and TNF-α (Fauci, 1996).  Among these cytokines, 
TNF-α is the most potent inducer of HIV-1 expression.  TNF-α activates the 
transcription factor NF-kB, which drives HIV-1 transcription by binding to the NF-κB 
binding site in the LTR of the HIV-1 genome (Fauci, 1996).  The molecular mechanisms 
by which other cytokines enhance HIV-1 replication remain to be elucidated.  IL-1α/β 
appear to increase transcription of HIV-1 without activating the NF-kB pathway, while 
IL-6 functions at post-transcriptional levels (Vicenzi et al., 1997).  In addition to the 
HIV-1-inducing cytokines, a number of β-chemokines produced by macrophages, 
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including MIP-1α, MIP-1β and RANTES, suppress HIV-1 replication in T cells 
(Vicenzi et al., 1997).  Since these chemokines are the natural ligands of CCR5 
receptors, which serve as co-receptors for the macrophage-tropic HIV-1, they 
downregulate HIV-1 replication largely by blocking viral entry (Fauci, 1996).  A third 
group of macrophage cytokines exert both inductive and suppressive effects on HIV-1 
replication.  These cytokines include IL-10, IFN-γ and TGF-β and are shown to affect 
multiple stages of the HIV-1 life cycle (Vicenzi et al., 1997).  The molecular 
mechanisms of their conflicting roles are unclear.   
It is hypothesized that HIV disease progression is due to an imbalanced T helper 
1/T helper 2 (Th1/Th2) response (Poli et al., 1995).  According to this hypothesis, Th1 
repsonse facilitate a protective cytotoxic T lymphocyte (CTL) response that is effective 
at clearing infected cells early in HIV-1 infection.  Over time, decreased production of 
IL-12 and increased production of IL-10 by macrophages, along with alteration of other 
Th1- and Th2-associated cytokines, suppress the Th1 response and result in a “shift” 
towards the Th2 response, which is unable to control the established viral infection (Poli 
et al., 1995).  This hypothesis has not been proven and is both supported and 
contradicted by results published by different investigators.  However, the Th1/Th2 
paradigm may be a valuable model to utilize when evaluating the immunologic 
significance of the various cytokines perturbed by other lentiviruses.   
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Clinical Signs of EIAV and Potential Roles of Cytokines in Pathogenesis 
 The clinical syndromes experienced by EIAV-infected horses are artificially 
divided into 3 stages: acute, chronic and inapparent (Fig. 2) (Sellon et al., 1994; Issel and 
Coggins, 1979).  However, these distinctions are not always clear as the clinical course 
of EIA is variable and depends on viral strains, environment and the horse’s immune 
status.  Acute EIA is associated with the initial exposure to the virus.  Viremia and 
clinical signs including fever, thrombocytopenia, hemorrhages, and anorexia become 
evident in 7-30 days post-infection.  Horses in the acute stage are usually seronegative as 
the immune system has not had enough time to produce antibodies.  Only rarely do 
horses die during the acute stage.  Most horses become afebrile for a period of time and 
then progress to chronic EIA, where the classic EIA symptoms are observed.  Chronic 
EIA is characterized by recurring episodes of fever, thrombocytopenia, anemia, 
anorexia, hemorrhages, viremia and diarrhea at varying intervals.  Most episodes occur 
within 30 days to one year post-infection, after which about 90% of infected horses 
become clinically normal and inapparent carriers.  In nature most EIA-positive horses 
detected by the AGID test are inapparent carriers.  They are important reservoirs of 
infection, and recrudescent EIA can be induced in these horses by immune-suppressive 
drugs or stress.  The most marked pathological features of a horse necropsied during a 
febrile episode include edema, thrombosis, splenomegaly, hepatomegaly, 
lymphodenopathy, infiltration of lymphocytes and macrophages in many organs and 
mucosal and visceral hemorrhages (Sellon et al., 1994; Issel and Coggins, 1979). 
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 The pathogenic mechanisms for the EIA symptoms are largely unknown.  
Because of the robust antibody response to EIAV infection, many of the symptoms are 
attributed to the detrimental effects of immune complexes.  For example, anemia is 
believed to be mediated by complement-mediated hemolysis and phagocytosis of 
erythrocytes coated with EIAV antigens or antigen-antibody complexes (Sentsui and 
Kono, 1987a; Chance et al., 1992).  Detection of increased platelet-bound 
immunoglobulin on platelets of thrombocytopenic horses also supports the hypothesis 
that deposition of EIAV-specific immune complexes on platelets promotes removal of 
circulating platelets by phagocytes of the spleen and liver (Clabough et al., 1991).  
However, the investigators are unable to demonstrate that the platelet-associated 
immunoglobulins are EIAV-specific (Clabough et al., 1991).  Moreover, 
thrombocytopenia occurs during acute-stage EIA when virus-specific antibody is not yet 
produced (Issel and Coggins, 1979).  EIAV-specific antibodies are also implicated in the 
glomerulitis and neurologic disorders associated with EIA (Sellon et al., 1994; 
Montelaro et al., 1993).  The conclusion that EIAV-specific antibodies are at best only 
partially responsible for inducing the symptoms of EIA is made evident by the findings 
that severe combined immunodeficient (SCID) horses develop fever, anemia and 
thrombocytopenia as severely as immunocompetent horses when experimentally 
infected with virulent strains of EIAV (Crawford et al., 1996; Tornquist et al., 1997).  
SCID horses lack functional T- and B-lymphocytes and are unable to mount antibody 
and CTL responses.  However, these horses have normal macrophage functions.   
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 Accumulating evidence shows that production of cytokines is dysregulated in 
EIAV-infected horses and might play important roles in EIAV pathogenesis.  Biological 
assays utilizing cytokine-sensitive cell lines reveal increased serum levels of TGF-β, TNF-α 
and IFN-α in SCID and immunocompetent Arabian foals infected with EIAV (Tornquist et 
al., 1997).  Furthermore, the plasma of EIAV-infected horses collected prior to or at the onset 
of thrombocytopenia suppresses proliferation of megakaryocyte colonies in culture, and this 
suppression was partly reversed by antibody neutralization of TGF-β and TNF-α (Tornquist 
and Crawford, 1997).  These results are supported by an earlier study that indicates in vivo 
suppression of platelet production in EIAV-infected SCID horses (Crawford et al., 1996).  
Platelets of thrombocytopenic EIAV-infected ponies also show signs of in vivo activation, 
which could result in aggregation, lysis, or “exhaustion” of platelets, causing accelerated 
platelet removal from the circulation (Russell et al., 1999).  A number of cytokines activate 
platelets or induce secretion of platelet-stimulating molecules (Oleksowicz et al., 1994; 
Oleksowicz et al., 1994; Tacchini-Cottier et al., 1998).  Taken together these reports suggest 
that EIAV-associated thrombocytopenia is caused by elevation of cytokines that suppress 
megakaryocytopoiesis and/or shorten the life span of circulating platelets.   
Occurrence of anemia in EIAV-infected SCID horses indicates that this symptom 
cannot be entirely attributed to immune-mediated destruction of peripheral erythrocytes.  
Swardson, et al., show that infection of bone marrow mononuclear cells with EIAV in vitro 
selectively suppresses the proliferation of burst-forming units-erythroid (BFU-E) and 
colony-forming units-erythroid (CFU-E) cells (Swardson et al., 1997).  Since EIAV does 
not establish a productive infection in erythroid progenitor cells, it is likely that infected 
macrophages secrete inhibitors of erythropoiesis.  IL-1 and TNF-α suppresses 
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erythropoiesis by downregulating erythropoietin production, impairing response of 
erythroid progenitors to erythropoietin, and dysregulating iron metabolism (Means, 
1997; Means, 2000).  Early literature reports reduced serum iron concentration, plasma 
iron turnover and iron utilization during acute EIA, suggesting suppression of 
erythropoiesis through a mechanism that is consistent with the activities of IL-1 and 
TNF-α (Swardson et al., 1997).   
In examining the disease enhancement effects of a p26 vaccine, Costa et al. noted 
a positive correlation between plasma TNF-α of EIAV-infected ponies and disease 
severity (Costa et al., 1997).  In this study, ponies infected with the virulent PV strain of 
EIAV (EIAVPV) develop acute fever, anemia and thrombocytopenia and present higher 
levels of TNF-α than those inoculated with the avirulent PR strain (EIAVPR), which do 
not develop clinical symptoms.  Vaccination enhances the severity of symptoms in both 
EIAVPR- and EIAVPV-infected ponies, as well as increases plasma TNF-α activity.  
These results advance the concept that EIAV infection causes the production of 
cytokines that contribute to the development of EIAV-associated diseases. 
 
Virulent EIAV Molecular Clones 
The exclusive tropism of virulent EIAV strains for equine macrophages and the 
difficulty of culturing primary macrophage have driven numerous efforts to derive 
virulent viruses that can be propagated in various cell lines.  Back-passaging the cell 
line-adapted avirulent EIAVPR in horses successfully generated the virulent virus stock 
EIAVPV, which retains the ability to grow in cell cultures (Rwambo et al., 1990; Issel et 
al., 1992).  However, genetically defined virulent molecular clones are needed to 
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manipulate and study EIAV at the molecular level.  Initially, molecular clones were 
directly obtained from the EIAVPV isolates by polymerase chain reaction (PCR) (Payne 
et al., 1994).  Viruses derived from these clones replicate to high titer in cell lines and 
primary equine macrophages but fail to cause disease in horses.  Finally, virulent EIAV 
molecular clones are successfully generated using chimeric techniques (Payne et al., 
1998; Cook et al., 1998).  Cook et al. produced infectious molecular clones by inserting 
a 3’ fragment that was PCR-amplified from EIAVPV-infected cells into a modified 
version of the avirulent clone pSPeiav19 (Cook et al., 1998).  Virus derived from one of 
these clones, EIAVUK, induces disease with varying severity in horses.  This virus has 
identical 3’ LTR, env, S3 (with a single amino acid change), S2 and S1 ORFs as the 
consensus EIAVPV sequence.   
In the generation of virulent chimeric molecular clones p19/wenv17 and 
p19/Wenv16, Payne et al. also utilize pSPeiav19 (Payne et al., 1998).  In contrast to the 
construction of EIAVUK, only the LTRs and the 3’ end of env (excluding the N-terminal 
89 amino acids) are replaced, and the inserted sequences are derived from EIAVWyo-
infected macrophages (Fig. 3A).  Viruses derived from these clones (EIAV17 and 
EIAV16) replicate to high titer in equine macrophages and cause EIA in infected 
Shetland ponies.  The symptoms induced by EIAV17 are particularly severe.  Sequence 
analyses show that differences in EIAV17 and EIAV16 from the parental pSPeiav19 are 
most striking in the SU region (Fig. 3B).  These differences concentrate in the principal 
neutralizing domain and the hypervariable region (Ball et al., 1992).  The TM region of 
env is more conserved with only scattered amino acid changes.  As the TM region  
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A
Fig. 3. Genomic organization and sequence comparisons of EIAV molecular clones.  (A) The 
schematic diagram indicates the origins of sequences used to construct the different regions of 
the chimeric virulent molecular clones p19/wenv17 and p19/wenv16.  (B) SU amino acid (aa) 
sequences of the avirulent pSPeiav19 are compared to the virulent p19/wenv17 and 
p19/wenv16.  Sequences shown start at the 144th aa of the SU as the sequences upstream are 
identical among the clones.  Sequences corresponding to the principal neutralizing and 
hypervariable domains are boxed.  Dashes indicate identical aa. Dots indicate aa deletions.  (C) 
The transcription enhancer regions within the 5’ U3 of EIAVWyo and EIAV molecular clones 
are compared.  Transcription factor binding sites are indicated by boxes.  The single nucleotide 
whereby EIAVWyo and the virulent molecular clones differ is highlighted in grey. 
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encompasses the second exon of the rev gene, substitution with Wyoming env also 
changes the amino acids in the Rev protein.  Notably, 1 and 3 amino acid substitutions 
occur in the Rev effector domain of p19/wenv17 and p19/wenv16, respectively.  Due to 
the cloning strategy, the U3-LTR of p19/wenv17 and p19/wenv16 are identical to the U3 
consensus sequence of Wyoming LTR (containing 3 ets, 1 CREB and no PEA2 sites) 
with a single G to C nucleotide substitution at the TATA-proximal ets binding site (Fig. 
3C).  In comparison, the U3-LTR of pSPeiav19 is typical of avirulent EIAV and 
contains 2 ets, 2 CREB and 2 PEA2 sites. 
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CHAPTER II 
 
SIMULTANEOUS QUANTITATION OF EQUINE CYTOKINE mRNAS USING A 
MULTI-PROBE RIBONUCLEASE PROTECTION ASSAY∗ 
 
Introduction 
Cytokine functions and interactions have primarily been elucidated in the rodent and 
human systems, which have provided useful paradigms for understanding other animal 
cytokines.  In contrast, characterization of equine cytokines is at a rudimentary stage.  
The scarcity of commercially available equine reagents has hindered the study of equine 
immunology resulting in a limited number of reports of a few equine cytokine responses.  
Cell line-based bioassay adaptations have been used to measure equine IL-2, IL-6, 
IFN, TNF-α, and  TGF-β1 (MacKay et al., 1991; Morris et al., 1992; Allen et al., 1993; 
Ellis et al., 1995; Charan et al., 1997), and antibodies specific to human or other animal 
cytokines were utilized to analyze equine IL-1β, IL-6, TGF-β, and TNF-α levels 
(Billinghurst et al., 1995; Charan et al., 1997; Rodriguez et al., 1996).  Recently, reverse 
transcription-polymerase chain reaction (RT-PCR), reverse transcription-competitive 
polymerase chain reaction (RT-cPCR) and Southern blot techniques were developed to 
measure equine cytokine mRNA levels (Grunig and Antczak, 1995; Rottman et al., 
1996; Byrne et al., 1997; Swiderski et al., 1999; Giguere and Prescott, 1999; 
                                                 
∗ Reprinted with permission from “Simultaneous Quantitation of Equine Cytokine 
mRNAs Using a Multi-Probe Ribonuclease Protection Assay” by W.-S. Lim et al., from 
Vet. Immunol. Immunopathol. Volume 91, 45-51, copyright © 2003 by Elsevier.  
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Leutenegger et al., 1999).  However, very few equine cytokines have been analyzed by 
the cell line- and antibody-based assays.  In addition, none of the currently available 
techniques allow rapid and simultaneous quantitative analysis of multiple equine 
cytokines.  
The goals of this study were to develop a set of RNA probes to simultaneously 
quantitate mRNA levels of an array of equine macrophage-specific cytokines and thus 
provide a useful tool for establishing cytokine profiles in response to equine diseases. 
Among the equine cytokines that are cloned or sequenced, IL-1α, IL-1β, IL-6, IL-8, IL-
10, IL-12 p35, IL-12 p40, IFN-γ, TGF-β1 and TNF-α are produced by macrophages and 
were included in our multi-probe ribonuclease protection assay (RPA) (Cavaillon, 1994; 
Gessani and Belardelli, 1998).   
 
Materials and Methods 
 
Cell culture   
Primary cultures of equine peripheral blood mononuclear cells (EPBMC) and 
equine monocyte-derived macrophages (EMDM) were established by a modification of 
the methods described by (Raabe et al., 1998).  Equine peripheral blood was collected 
into citrate dextrose solution and centrifuged at 700×g for 30 min to separate the buffy 
coats.  EPBMC were extracted from buffy coats by centrifugation through a HybriMax 
Histopaque (d=1.077 g/cm3) cushion (Sigma, St. Louis, MO); washed 4 times with Ca2+, 
Mg2+-free PBS, 5% adult horse serum (HyClone, Logan, Utah); resuspended in MEMα 
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medium with 10% adult horse serum (GIBCO BRL, Rockville, MD), 25 mM HEPES, 
100 IU/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, 0.1 mM non-essential 
amino acids and 1 mM sodium pyruvate (complete MEMα); seeded at 5×106 cells/cm2; 
and incubated overnight at 37°C, 5% CO2.  Nonadherent cells were removed and 
adherent monocytes were incubated for 7 days to allow differentiation into macrophages 
(EMDM).   
 
Construction of template plasmids 
Equine cytokine sequences published in GenBank database were used to design 
RT-PCR primer pairs (Table 2 and 3).  These primers were chosen to obtain a set of 
cytokine cDNAs that could then be utilized to generate probes and protected fragments 
ranging from 100 to 430 nucleotides in length (Table 2), the optimal range for separation 
on 5% acrylamide gels (Bellin, 1996; Farell, Jr., 1998).  A Hind III restriction enzyme 
site was incorporated into the 5’ ends of all the reverse primers to facilitate cloning into 
the plasmid vector (Table 3).  A BamH I site was incorporated into the 5’ end of the 
forward primers for IL-6, IL-8, IL-10, IL-12 p35, IL-12 p40, IFN-γ, TNF-α and β-actin.  
An EcoR I site was incorporated into the 5’ ends of the forward primers for IL-1α, IL-
1β, and TGF-β1.   
EPBMC and equine monocytes were stimulated with 50 µg/ml of ConA (Sigma) for 
4 hours at 37°C and total RNA was extracted using the GLASSMAX RNA Microisolation 
Spin Cartridge System (GIBCO BRL, Rockville, MD) following the manufacture’s 
instructions.  Eight 1.5 µg aliquots of total RNA from EPBMC were reverse-transcribed  
Table 2 
cDNAs of cytokine and internal control genes included in the template set and 
expected sizes of full-length probes and protected fragments 
 
Cytokine 
Nucleotide 
numbers Size (bp) 
GenBank 
accession 
number 
  Full-length 
probe 
Protected 
fragment 
  
IL-1α 5-385 399 381 U92480 
IL-1β 562-974 430 413 U92481 
IL-6 57-394 357 338 U64794 
IL-8 61-230 189 170 AF062377 
IL-10 377-557 196 181 U38200 
IL-12 p35 34-171 150 138 Y11130 
IL-12 p40 568-681 133 114 Y11129 
IFN-γ 204-470 285 267 D28520 
TGF-β1 496-739 263 244 AF175709 
TNF-α 1-206 223 206 AB035735 
β-actin 861-960 119 100 AF035774 
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Table 3 
Sequences of primers used to generate equine cytokine cDNA fragments 
Cytokine Forward primer (5’-3’) a Reverse primer (5’-3’) 
IL-1α CGGAATTCTTTCACTGGCACTTGAGTCG CCCAAGCTTAATGTACTGATCGGGGCTTG 
IL-1βb CGGAATTCGACTGACAAGATACCTGTGGCCT CCCAAGCTTAGACAACAGTGAAGTGCAGCCT 
IL-6 CGGGATCCCCTGGTGATGGCTACTGCTT CCCAAGCTTCCTTGAACTCGTTCTGGAGG 
IL-8 CGGGATCCGAAGCTGCGGTTGTATCAAG CCCAAGCTTCAGACCTCAGCTCCGTTGAC 
IL-10 CGGGATCCGTCATCGATTTCTGCCCTGT CCCAAGCTTCGTTCCCTAGGATGCTTCAG 
IL-12 p35 CGGGATCCTGGTCCTCCTAAACCACCTG CCCAAGCTTCTGAAGCGTGTTGCTGAC 
IL-12 p40 CGGGATCCTACACGGTGGAGTGTCAGGA CCCAAGCTTGCCGCTGGTGTAGTTTTCAT 
IFN-γ CGGGATCCTCAGAGCCAAATCGTCTCCT CCCAAGCTTTCTGACTCCTCTTCCGCTTC 
TGF-β1 CGGAATTCAGTTAAGCGTGGAGCAGCAT CCCAAGCTTCTGGAACTGAACCCGTTGAT 
TNF-α CGGGATCCCAGCTGGACTTGAGCCCCT CCCAAGCTTGCCGATCACCCCAAAGTG 
β-actin CGGGATCCCGACATCCGTAAGGACCTGT CCCAAGCTTCAGGGCTGTGATCTCCTTCT 
a Sequences in italic are restriction enzyme cleavage sites: GAATTC, EcoR I; GGATCC, BamH I; AAGCTT, Hind III.  CG 
or CCC nucleotides were incorporated into the 5’ ends of the primers to increase the efficiency of restriction enzyme digestion.  
b This pair of primers was derived from primer sequences described by Giguere and Prescott (1999)  
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into first-strand cDNA for IL-1α, IL-1β, IL-8, IL-12 p35, IFN-γ, TGF-β1, TNF-α and β-
actin using the corresponding reverse primers (Table 3) and either M-MLV or AMV  
reverse transcriptase (Promega Corporation, Madison, WI) following the manufacture’s 
instructions.  IL-12 p40 cDNA was synthesized from total RNA of equine monocytes. 
The cDNAs for IL-1α, IL-1β, IL-8, IL-12 p35, IFN-γ, TGF-β1, TNF-α and β-actin 
were amplified by PCR using the primer pairs shown in Table 3 under the following  
conditions: initial denaturation for 2 minutes at 95°C followed by 35 cycles of 1 minute 
at 94 °C, 1 minute at 54°C, 1 minute at 72°C, followed by 6 minutes at 72°C.  IL-12 p40 
cDNA was amplified under the same conditions except the annealing temperature was 
increased to 60°C to eliminate nonspecific products.   
IL-6 and IL-10 fragments were amplified from plasmids (pCREQIL6 and 
pCREQIL10 respectively) containing the complete equine IL-6 and IL-10 genes (kindly 
provided by David W. Horohov, Louisiana State University), using primer pairs shown 
in Table 3 and the PCR conditions described above (with annealing temperature at 
54°C).  All cDNAs were phenol extracted and subjected to an additional round of PCR 
to obtain sufficient product for cloning into pGEM-4Z (Promega).   
 cDNA fragments of IL-6, IL-8, IL-10, IL-12 p35, IL-12 p40, IFN-γ, TNF-α and 
β-actin were digested with Hind III and BamH I (Promega Corp.) and cloned into Hind 
III and BamH I digested pGEM-4Z (Promega Corp.).  The cDNA fragments of IL-1α, 
IL-1β, TGF-β1 were digested with Hind III and EcoR I (Promega Corp.) and cloned into 
Hind III and EcoR I digested pGEM-4Z.  This cloning strategy ensured that the inserted 
cDNA fragments were oriented such that antisense RNAs were synthesized when the 
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templates were transcribed with T7 RNA polymerase. Template plasmids were 
sequenced using pUC/M13 or M13 Universal forward and reverse sequencing primers to 
confirm orientation and agreement with published sequences.   
 
Radiolabeled RNA probes   
Plasmids containing IL-6, IL-8, IL-10, IL-12 p35, IL-12 p40, IFN-γ, TNF-α and 
β-actin were linearized by BamH I digestion, and those containing IL-1α, IL-1β and 
TGF-β1 were linearized by EcoR I digestion.  Radiolabeled negative-strand RNA probes 
were generated using the RiboProbe In vitro Transcription System (Promega Corp.) 
according to the manufacture’s specified protocols.  Each linearized template (0.1-0.5 
µg) was mixed with 1× Transcription Optimized Buffer, 10 mM DTT, 10 units 
recombinant Rnasin RNase inhibitor, 2.5 mM each of rATP, rGTP, and rUTP, 100 µM 
rCTP, 50 µCi [α-32P]rCTP (NEN, Boston, MA) and 7.5 units T7 RNA polymerase, and 
incubated at 37°C for 1 hour.  DNA templates were removed by treating each reaction 
with 0.5 units of RQ1 RNase-free DNase.  Full-length probes were gel purified on 5% 
acrylamide/8 M urea denaturing gels. (5% acrylamide [acrylamide: bis acrylamide = 19 : 
1], 8 M urea, 1× Tris-Borate-EDTA buffer, 0.08% ammonium persulfate, 0.1% 
TEMED).  Gel slices containing full-length probes were excised from the gel, 
submerged in 80 µl of DEPC-treated water, and incubated for 4 hours at 37°C to elute 
the probes.   
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Nonradiolabeled IL-1β RNA   
To synthesize positive-strand IL-1β RNA, the plasmid containing IL-1β was 
linearized by Hind III digestion and in vitro transcribed using SP6 RNA polymerase in 
the presence of nonradiolabeled rCTP.  Integrity of the RNA was verified by gel 
electrophoresis and the concentration was estimated by UV spectrophotometry.  The 
positive-strand IL-1β RNA was serially diluted with MA104 (simian kidney, ATCC) 
cell lysates (5×106 cells/ml) to 1.5×109, 3×108; 6×107, 1.2×107, 2.5×106; 5×105; 1×105, 
2×104 and 0 molecules per 45 µl. 
 
RPA 
RPA was performed using the Direct Protect Lysate RPA kit (Ambion, Austin, 
TX).  For measurement of EMDM cytokines, EMDM cultured for 7 days were re-seeded 
onto 6-well plates at 2×105 cells/well, stimulated with 0 or 10 µg/ml of LPS (from 
0111:B4 E. coli, Sigma) for 4 hours, and harvested by trypsinization.  Pelleted EMDM 
were lysed with Lysis Solution (Ambion) and stored at −20°C.  For each hybridization 
reaction, 45 µl of cell lysate (from 2×105 cells) was incubated with 5 µl of probe mixture 
that contained ~9×104 cpm of each of the 11 equine cytokine probes.  Negative controls 
included 5 µl of probe mixture only and 5 µl of probe mixture incubated with 10 µg of 
yeast tRNA (Ambion).  Reaction mixtures were incubated at 37°C overnight, treated 
with 5 U of RNase A and 200 U of RNase T1, and incubated for 30 min at 37°C in 1× 
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RNase Digestion Buffer.  The probes-only control was treated with 1× RNase Digestion 
Buffer in the absence of RNase.  Digestion was stopped by adding 10 µl of Proteinase K 
(20 mg/ml) and 20 µl of 10% Sodium Sarcosyl and incubating for 30 min at 37°C.  RNA 
was precipitated from each reaction with isopropanol and pellets were washed with 
ethanol, air-dried, resuspended in Gel Loading Buffer II (Ambion), heated (95°C, 3 
min), and resolved on a 5% acrylamide/8 M urea denaturing gel at 400 V for 3.5 h.  An 
aliquot of the probes-only control containing ~9×103 cpm of each probe was applied to 
the gel as a negative control.  
For measurement of EPBMC cytokines, EPMBC isolated from horse blood were 
seeded onto 12-well plates at 8×106 cells/well and immediately stimulated with 25 µg/ml 
ConA for 24 hrs.  After the incubation, both the adherent and nonadherent EPBMC were 
harvested and lysed.  Lysates equivalent to 7×105 EPBMC were analyzed by RPA.  
Quantitation of EMDM and EPBMC cytokine mRNAs was performed in triplicate using 
cells maintained in separate cultures.   
To evaluate reproducibility, a single flask of EMDM cells was stimulated with 10 
µg/ml of LPS for 4 h.  Four equivalent aliquots (7×105 cells) of the lysate were used to 
perform four independent RPA. 
 
Quantification of Cytokine mRNA Levels 
To quantify cytokine mRNA expression levels, the dried gel was exposed to a 
Fujifilm Imaging Plate and scanned with a Fujifilm Bio-imaging Analyzer BAS-1800II  
(Kanagawa, Japan).  The photo-stimulated luminescence (PSL) released by the radiated 
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Imaging Plate was analyzed with the ImageGauge™ imaging analysis software (Version 
3.12, Science Lab/Fuji Photo Film Co., Ltd.) to generate a graphical representation of 
the PSL of each lane (Fig. 4).  The areas under the curves, calculated as integrated PSL, 
are directly proportional to the amount of radioactivity of the protected probes.  
Background (BG) level of each band was automatically calculated and subtracted from 
the integrated PSL (PSL-BG). To normalize for differences in input RNA and gel 
loading, cytokine mRNA levels were expressed as a percentage of β-actin mRNA and 
were calculated as follows: 
 
 
Results 
All template plasmids were sequenced and shared 100% identity with the 
published cDNA sequences of these genes.  Radiolabeled RNA probes of the expected 
sizes were generated (Fig. 5A, lane 1).  Probes for IL-1α, IL-1β, IL-6, IL-8, IL-10, TGF-
β1, TNF-α and β-actin produced protected fragments of the expected size after 
hybridization with EMDM lysates (Fig. 5A).  All probes and protected fragment lengths 
differed from each other by at least 10 nucleotides allowing simultaneous analysis of all 
10 cytokines and the β-actin control.  Protection of these probes was sequence-specific 
since yeast tRNA failed to protect any of the probes from digestion.   
To determine whether the lack of IFN-γ detection was due to the absence of IFN-
γ mRNA in EMDM or failure of the probe to protect the mRNA, cytokine expression of 
EPBMC was analyzed by the multi-probe RPA.  The IFN-γ probe generated a protected  
PSL – BG of β-actin 
PSL – BG of cytokine × 100% 
PS
L
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625.9 71.04 18.69 47.95 78.46 3924 3420117
β-actinIL-1β IL-1α TGF-β1 TNF-α IL-10 IL-8IL-6Cytokines
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Fig. 4. Quantification of equine cytokine mRNAs as measured by phosphor imaging.  A Fujifilm Phosphor Imaging Plate was exposed to gels 
containing the protected fragments of the radioactive RNA probes and scanned with a Fujifilm Bio-imaging Analyzer BAS-1800II.  The
ImageGauge™ software was employed to generate a graphical representation of the bands in each lane.  The x-axis depicts the distance of the 
bands from the top of the gel.  The y-axis shows the photo-stimulated luminescence (PSL) released by the radiated Imaging Plate.  Shaded areas 
under the curve are calculated as integrated PSL, which are directly proportional to levels of radioactivity.  Background level s are automatically 
calculated and subtracted.  The names of the cytokine genes and corresponding background-corrected PSL values are indicated across the top of 
the figure. 
  
44
IL-1β
IL-1α
IL-6
IL-10
IL-8
IL-12 p35
IL-12 p40
β-actin
IFN-γ
TGF-β1
TNF-α
400 ntds
300 ntds
200 ntds
100 ntds
1 2 3 4 5 6  87
A
Fig. 5. Phosphor image of a 5% acrylamide/8M urea denaturing gel showing the relative migration 
of full-length RNA probes and protected fragments (Panel A), and the detection of ΙFN-γ  in 
EPBMC (Panel B).  (A) Eleven radiolabeled RNA probes (10 equine-specific cytokines and β-
actin control) were hybridized to yeast tRNA (lanes 1 and 2) or EMDM lysates (lanes 3 to 8).  
Reactions were either undigested (lane 1) or digested with RNases (lanes 2 to 8).  The probes were 
hybridized with EMDM lysates that were stimulated 4 h at 37°C with 0 µg/ml (lanes 3, 5 and 7) or 
10 µg/ml of LPS (lanes 4, 6 and 8).  The molecular weights of the RNA standards are indicated on 
the right of the gel.  Depicted on the left are the locations of each full-length probe and the 
corresponding protected fragment(s) when present.  The β-actin protected fragments appear as 3 
bands in EMDM.  (B) To verify that the probe for IFN-γ was correct and could detect the presence 
of IFN-γ mRNA, EPBMC lysates were examined by RPA. Radiolabeled probes were hybridized 
to either yeast tRNA (lane 1 and 2), unstimulated EPBMC lysates (lane 3), or EPMBC lysates
stimulated with 25 µg/ml of ConA for 24 h at 37°C.  With the exception of lane 1, all samples were 
digested with RNases.  RNA molecular weights standards are indicated on the right, and the 
locations of each full-length probe and the corresponding protected fragment(s) when present are 
specified on the left.  In contrast to EMDM, the β-actin protected fragments are 2 bands in 
EPBMC.  Data shown are representative of experiments done in triplicate.
 
 
45
IL-1β
IL-6
IL-10
IL-8
IL-12 p35
IL-12 p40
β-actin
*IFN-γ
TGF-β1
TNF-α
IL-1α
1 2 3 4
B
400 ntds
300 ntds
200 ntds
100 ntds
Figure 5.  Continued..
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fragment of the expected size after hybridization with EPBMC lysates (Fig. 5B).  IL-1α, 
IL-1β, IL-6, IL-8, TGF-β1 and TNF-α mRNAs also were detected in EPBMC, however 
protected fragments of IL-10, IL-12 p35 and IL-12 p40 were not discerned (Fig. 5B). 
These data demonstrate the multi-probe RPA can detect the expression of IFN-γ mRNA 
and the assay can be readily adapted to analyze cytokine mRNA expression in EPBMC.   
The levels of cytokine mRNAs in EMDM were quantified by phosphor images 
of the protected probe fragments and normalized to the β-actin mRNA level (Table 4).  
In unstimulated EMDM, cytokine mRNAs were essentially undetectable with the 
exception of IL-8 and TGF-β1, which were weakly expressed at 1.53% and 0.67% β-
actin levels, respectively.  LPS stimulation of EMDM upregulated expression of IL-1α 
to 1.96%, IL-1β to 18.22%, IL-6 to 3.24%, IL-8 to 116.70%, IL-10 to 2.32% and TNF-α 
to 1.81%, but slightly downregulated expression of TGF-β1 to 0.61% (Table 4).  
Expression of IFN-γ mRNA, undetectable in unstimulated EPBMC, was increased by 
ConA stimulation to 0.59%.  Neither IL-12 p35 nor IL-12 p40 were detected in 
unstimulated or stimulated EMDM or EPBMC.  These results demonstrate the capability 
of the multi-probe RPA to simultaneously quantitate the mRNA levels of IL-1α, IL-1β, 
IL-6, IL-8, IL-10, IFN-γ, TGF-β1 and TNF-α in a single experiment.   
To verify that β-actin mRNA levels in EMDM are not affected by LPS 
stimulation, 7 day-old EMDM were seeded in 6-well plates at 2×105 cells/well and 
incubated with 0 or 10 µg/ml LPS for 4 h.  EMDM lysates were hybridized with ~9×104 
cpm of β-actin probe and analyzed by RPA (Fig. 6A).  Comparison of mean β-actin  
 
Table 4 
Cytokine mRNA levels in EMDM and EPBMC analyzed by multi-probe RPA 
Normalized mRNA levels (% β-actin)b 
Cytokinesa 
Unstimulated  LPS- or ConA-Stimulated 
IL-1α U.D.c 1.96±0.11 
IL-1β U.D. 18.22±0.32 
IL-6 U.D. 3.24±0.18 
IL-8 1.53±0.32 116.70±1.71 
IL-10 U.D. 2.32±0.28 
TGF-β1 0.67±0.13 0.61±0.14 
TNF-α U.D. 1.81±0.35 
IFN-γ U.D. 0.59±0.08 
a mRNA levels of IL-1α, IL-1β, IL-6, IL-8, IL-10, TGF-β1 and TNF-α 
were quantitated in EMDM stimulated with 0 and 10 µg/ml LPS for 4 h. 
mRNA levels of IFN-γ were quantitated in EPBMC stimulated with 0 and 
25 µg/ml of ConA for 24 h.  
b mRNA levels are expressed as a percentage of the control β-actin 
mRNA levels.  The data shown are means ± standard deviation of triplicate 
experiments. 
c Undetectable. 
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Fig. 6. Suitability of the β-actin internal control and sensitivity of the RPA. (A) Expression of β-
actin mRNAs in unstimulated and LPS-stimulated EMDM. Radiolabeled β-actin probe was 
hybridized with EMDM lysates, treated with RNases, and analyzed by gel electrophoresis and 
phosphor imaging.  Lane 1 shows the migration of the full-length β-actin probe.  Lanes 2 – 4 show 
β-actin from unstimulated EMDM; lanes 5-7 show β-actin from LPS-stimulated EMDM.  (B) 
Graphical representation of mRNA levels of β-actin shown in A.  The x-axis indicates stimulation of 
EMDM.  The y-axis depicts the β-actin mRNA levels.  The data shown are means ± standard 
deviation of triplicate experiments. (C) Sensitivity of the RPA using IL-1β as target. Positive-strand
nonradiolabeled IL-1β was in vitro transcribed and added to MA104 cell lysates. Radiolabeled IL-
1β probe was then hybridized with the lysates, treated with RNases, and analyzed by gel 
electrophoresis and phosphor imaging.  Lane 1 shows the full-length IL-1β probe.  Based on UV
spectrophotometry estimations, the following numbers of target molecules were added to MA104
lysates prior to RPA: lane 2, 1.5×109; lane 3, 3×108; lane 4, 6×107; lane 5, 1.2×107; lane 6, 2.5×106; 
lane 7, 5×105; lane 8, 1×105; lane 9, 2×104.   In lane 10, positive-strand IL-1β target was not added 
to the MA104 cell lysate. 
 
 
49
 
 
50
mRNA levels showed that unstimulated and stimulated EMDM expressed equivalent 
levels of β-actin (Fig. 6B).  Thus, β-actin is a suitable internal control for quantitation of 
LPS-stimulated EMDM cytokines (Suzuki et al., 2000).  However, when measuring 
cytokine responses to other treatments or in other equine cells, it will be necessary to 
reevaluate the use of β-actin as an apposite internal control.   
To assess the sensitivity of the RPA, nonradiolabeled positive-strand IL-1β was 
generated and used as synthetic targets.  Varying numbers of target molecules were 
diluted in MA104 lysates, hybridized with ~9×104 cpm of radiolabeled anti-sense IL-1β 
probe, and analyzed by RPA.  5×105 molecules of target were detectable (Fig. 6C), akin 
to other RPA techniques (Haines and Gillespie, 1992). 
The reproducibility of the RPA was evaluated by analyzing 4 equivalent aliquots 
(7×105 cells per aliquot) of the lysate derived from a single culture flask of LPS-
stimulated EMDM.  The dried gel was quantitated by phosphor imaging as described 
above (Table 5).  The coefficient of variation (CV) of the unnormalized cytokine mRNA 
levels ranged from 0.11 to 0.17.  Since the same amount of a common lysate was used in 
each assay, the variations were likely due to handling of the samples and gel loading.  
When the cytokine mRNA levels were normalized by the concentration of β-actin 
mRNA, the CV was markedly decreased by 1.5-5.7 fold to 0.03-0.08 (Table 5).  It is 
unlikely this level of reproducibility will be attained with experimental samples. 
 
 
 
 
 
 
 
 
 
 
Table 5 
Reproducibility of the multi-probe RPA and effects of β−actin normalization 
Unnormalized mRNA Levels   β-actin Normalized mRNA LevelsCytokine Meana SDb CVc  Mean SD CV 
IL-1α 2580.69 437.88 0.17  2.00 0.05 0.03 
IL-1β 6097.66 873.84 0.14  4.75 0.32 0.07 
IL-6 1823.41 219.53 0.12  1.43 0.11 0.08 
IL-8 217812.75 26003.42 0.12  170.20 9.47 0.06 
IL-10 11817.41 1580.75 0.13  9.22 0.62 0.07 
TGF- β1 2012.91 223.21 0.11  1.27 0.08 0.05 
TNF-α 9604.38 1321.41 0.14  7.49 0.24 0.03 
aMean cytokine mRNA levels measured by 4 individual assays using aliquots of a 
common LPS-stimulated EMDM lysate. 
bStandard deviation. 
cCoefficient of variation. 
 
 
 
 
 
 
 
 
 
 
 
51
 
 
52
Discussion 
This study shows the successful development of a RPA that simultaneously 
analyzes the mRNA expression of equine IL-1α, IL-1β, IL-6, IL-8, IL-10, IFN-γ, TGF-
β1 and TNF-α in EMDM and EPBMC cultures.  In the course of developing the RPA, a 
set of 11 template plasmids were generated from which antisense RNA probes specific 
to 10 equine cytokine genes and the equine β-actin gene were synthesized by in vitro 
transcription.  By using the equine β-actin to normalize the sample-to-sample 
differences, the assay had a CV of 0.03-0.08 (or 3%-8%).  In a previously reported RPA, 
a fixed amount of in vitro-transcribed RNA was added as an internal control, resulting in 
a between-assay CV of 11.3% (Petersen et al., 1995).   By comparison, the RPA 
described in this study is highly precise and reproducible.  This assay detected as few as 
5×105 molecules of target RNA, similar to the sensitivity of a previously characterized 
lysate-based RPA, which detects 104-105 target mRNAs (Haines and Gillespie, 1992).   
The results presented herein show that the transcription of IL-1α, IL-1β, IL-6, IL-8, 
IL-10, and TNF-α genes in EMDM was induced by LPS.  Similarly, LPS upregulates 
the transcription of these cytokine genes in human macrophages (de Waal et al., 1991; 
Springs et al., 1992; Zhong et al., 1993).  In contrast, mRNA of TGF-β1 was 
constituitively expressed in EMDM and was slightly downregulated by LPS.  In human 
monocyte cultures, TGF-β1 is also expressed constituitively (Toossi et al., 1995).  LPS 
stimulation accelerates the decay of TGF-β1 mRNA resulting in a decrease of steady 
state mRNA levels when analyzed by Northern blot (Toossi et al., 1995). 
 
 
53
The multi-probe RPA revealed that ConA stimulation of EPBMC increased mRNA 
levels of IL-1α, IL-1β, IL-6, IL-8, IFN-γ and TNF-α and decreased mRNA level of 
TGF-β1.  Upregulation of IL-1α, IL-1β, IL-6, IFN-γ and TNF-α has been shown in 
ConA stimulated EPBMC using RT-cPCR.  Moreover, in agreement with the RPA 
results, the RT-cPCR results also show that the increase of IFN-γ mRNA levels is 
greater than the other cytokines tested after 24 hrs of ConA stimulation (Giguere and 
Prescott, 1999; Rottman et al., 1996).  The report by Giguere and Prescott shows mRNA 
expression of IL-10, IL-12 p35 and IL-12 p40 at 0.18-5.74×104 molecules per µg of total 
RNA upon stimulation of EPBMC.  In contrast, the RPA failed to detect these cytokines.  
Although it is known that the RT-cPCR technique is more sensitive, RPA allows more 
rapid evaluation of multiple cytokines. 
In summary, the cytokine mRNA profiles of LPS-stimulated EMDM as measured 
by our multi-probe assay are consistent with those of equivalent human systems.  The 
cytokine mRNA profiles of ConA-stimulated EPMBC are also in general agreement 
with the EPBMC cytokine mRNA profiles previously analyzed by RT-cPCR assay.  
Taken together, these results show that the equine-specific multi-probe RPA is highly 
accurate and dependable, albeit not as sensitive as the RT-cPCR approaches.   
This is the first RPA designed to measure mRNA expression of equine cytokines.  
Although tested in primary EMDM and EPBMC, this assay should be applicable to other 
equine cells or tissues.  The specificity, precision, sensitivity, and simultaneous 
quantitation capability of this assay make it an extremely useful tool in the analysis of 
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equine cytokines and will enhance our understandig of equine immunology and disease 
pathogenesis. 
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CHAPTER III 
 
DIFFERENTIAL EFFECTS OF VIRULENT AND AVIRULENT EQUINE 
INFECTIOUS ANEMIA VIRUS MOLECULAR CLONES ON PRIMARY 
EQUINE MACROPHAGE CYTOKINE EXPRESSION 
 
Introduction 
Equine infectious anemia virus (EIAV) belongs to the family Retroviridae, genus 
lentivirus.  The clinical course of EIAV infection is classically divided into acute, chronic, and 
inapparent carrier phases.  The acute phase occurs within 5-30 days post-infection (dpi) and is 
characterized by viremia, fever, and thrombocytopenia (Sellon et al., 1994; Issel and Coggins, 
1979).  The acute symptoms vary from mild to severe to fatal depending on the strain of EIAV 
and the host immune status.  Following the acute phase, the infected animal may develop 
chronic EIA which manifests as recurring cycles of fever, severe anemia, weight loss, 
thrombocytopenia, hemorrhages, and anorexia (Issel and Coggins, 1979).  About 90% of 
infected horses survive the chronic phase and become clinically normal.  Subsequent clinical 
episodes can be elicited in inapparent carriers by environmental stress or immune-suppressive 
drugs (Cheevers and McGuire, 1985).  As in all retroviral infections, infected horses remain 
life-long carriers of EIAV (Issel and Coggins, 1979; Kono et al., 1976).   
Tissue macrophages are the primary sites for EIAV replication and serve as cellular 
reservoirs during acute and persistent infection (Sellon et al., 1992; Oaks et al., 1998).  EIAV 
can infect circulating monocytes, but virus expression is limited to differentiated tissue 
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macrophages.  Macrophages are the source of a myriad of cytokines, and perturbation of 
cytokine expression has been shown in other lentivirus-infected macrophages including 
human and simian immunodeficiency viruses (HIV, SIV respectively), caprine arthritis 
encephalitis virus (CAEV) and maedi-visna virus (MVV) (Bornemann et al., 1997; Sopper et 
al., 1996; Zink et al., 2001; Horvath et al., 1991; Lechner et al., 1997; Adeyemo et al., 1997; 
Ebrahimi et al., 2000; Legastelois et al., 1998; Legastelois et al., 1997; Legastelois et al., 
1996).  Cytokines produced by infected macrophages have been shown to impact the outcome 
of lentiviral infections.  For example, interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-
α) contribute to the neurological impairment associated with late-stage HIV and SIV infection 
by facilitating infiltration of macrophages into the CNS and stimulating production of 
neurotoxic substances by activated macrophages and microglia (Orandle et al., 2001; Sopper 
et al., 1996; Xiong et al., 2000; Tan and Guiloff, 1998).  Macrophage-secreted cytokines and 
chemokines, including IL-1, IL-6, type I interferons (IFN), TNF-α, RANTES and macrophage 
inflammatory proteins-1α and 1β (MIP-1α and 1β), are known to regulate the expression and 
replication of HIV in macrophages and CD4+ T-lymphocytes (Vicenzi et al., 1997; Fauci, 
1996).  Therefore, investigating the interaction of EIAV with equine monocytes and 
macrophages is important to the study of EIAV-induced disease.   
In this study, viruses derived from two EIAV molecular clones, pSPEIAV19 and 
p19/wenv17, were examined for induction of cytokines in equine monocyte-derived 
macrophages (EMDM).  Virus derived from clone pSPEIAV19 (EIAV19) causes asymptomatic 
infection in Shetland ponies (Payne et al., 1994).  p19/wenv17 is a chimeric clone generated 
by replacing the 5’ and 3’ long terminal repeats (LTR) and the env sequences of pSPEIAV19 
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with those derived from the highly virulent Wyoming field strain EIAV (EIAVWyo) (Payne et 
al., 1998).  p19/wenv17 produces a virus, named EIAV17, that causes severe EIA in all 
infected Shetland ponies (Payne et al., 1998).  In vitro, however, both viruses replicate to high 
titer and induce cytopathic effects (CPE) in EMDM, indicating the difference in their clinical 
manifestations are due to factors other than differential levels of viral expression in 
macrophages.  Cytokine profiles of EMDM infected with EIAV19 or EIAV17 were determined 
to evaluate the correlation between cytokine dysregulation and EIAV pathogenesis.  We 
utilized a newly developed set of antisense RNA probes to quantitate the mRNA expression of 
10 equine cytokine genes by ribonuclease protection assay (RPA) (Lim et al., 2003a). 
 
Materials and Methods 
 
Cell culture   
Primary EMDM culture was established as previously described (Lim et al., 
2003a).  Briefly, anticoagulated equine peripheral blood from EIA-negative donor horses 
was centrifuged to separate the buffy coat, which was then centrifuged through a 
HybriMax Histopaque cushion (d=1.077 g/cm3; Sigma, St. Louis, MO) to extract equine 
peripheral blood mononuclear cells (EPBMC).  EPBMC were washed 4 times, 
resuspended in minimum essential medium alpha (MEMα) containing 10% adult horse 
serum (GIBCO BRL, Rockville, MD), 25 mM HEPES, 100 IU/ml penicillin, 100 µg/ml 
streptomycin, 2 mM L-glutamine, 0.1 mM non-essential amino acids and 1 mM sodium 
pyruvate (complete MEMα), seeded at 3×106 cells/cm2 into tissue culture flasks and 
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incubated overnight.  Nonadherent cells were removed, and the adherent monocytes 
were washed twice and incubated for 7 days to allow maturation into macrophages.  
Purity of the macrophage culture was estimated at 95% by the α-nalphthyl acetate esterase 
assay (Sigma kit no. 91-A) and by immunofluorescent microscopy using a monoclonal 
antibody (I.646) specific to a cytoplasmic antigen of equine mononuclear phagocytes (gift of 
F. J. Fuller; Sellon, 1993).   All reagents used in EMDM culture were tested for endotoxin by 
the Limulus amebocyte lysate (LAL) assay (Associates of Cape Cod Inc., Falmouth, MA).  
Reagents with an endotoxin level of 0.06 EU/ml or lower were considered suitable for our 
assays.  Horse sera containing less than 0.5 EU/ml (as tested by the manufacture) were 
purchased. 
D17 cells (ATCC CCL-183), a cell line derived from canine lung osteosarcoma, 
were cultured in MEM containing 10% fetal bovine serum (BioWhittaker) in 25-cm2 
flasks as previously described (Payne et al., 1998). 
 
Generation of virus stocks 
EIAV19 and EIAV17 are derived from pSPEIAV19 and p19/wenv17 plasmids, 
respectively, as reported (Payne et al., 1998).  Briefly, D17 cells were plated in 60 mm 
dishes at 2.5 x 105 cells per dish 18-24 h prior to transfection (Calcium Phosphate 
Transfection System, Life Technologies).  Each dish of cells was incubated with 10 µg 
of plasmid for 1.5 hours at 37°C, washed twice with phosphate buffered saline (PBS), 
and replenished with fresh media. Virus production was monitored by reverse 
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transcriptase (RT) assay of culture supernatants as previously described except that 
[3H]TTP was used instead of [32P]TTP (Gregersen et al., 1988).   
Virus stocks were amplified by infecting EMDM at approximately 5×10-3 counts 
per min (cpm) of RT activity per cell.  Culture supernatants of infected EMDM were 
collected when approximately 80% of the cells displayed CPE (7 to 12 dpi).  Growth of 
virus was verified by increases in RT activity. To remove cell-secreted molecules 
(especially cytokines), 100 ml of infected culture supernatant was sterilely ultra-filtered against 
1L of fresh complete MEMα (without horse serum) using a Vivaflow 200 tangential-flow 
ultra-filtration unit with a MWCO of 100 kDa (Sartorius Corp, Edgewood, New York).  The 
100-kDa filter was chosen because the molecular weights of cytokines range from 7 to 75 
kDa.  Ultra-filtration of 100 ml of 50 mg/ml purified bovine serum albumin (66 kDa) solution 
using these conditions removed 96% of the protein from solution (data not shown).  After 
ultra-filtration, RT activity of the virus was re-measured and infectivity was verified by growth 
in EMDM.  Culture supernatant of mock-infected EMDM was collected and purified under 
the same conditions, and was termed control medium (CM). Purified CM, EIAV19 and 
EIAV17 contained negligible levels of endotoxin (0.12-0.25 EU/ml). 
 
Western blot 
Aliquots of EIAV19 and EIAV17 stocks containing 60,000 cpm of RT activity were 
pelleted by centrifugation at 13,000× g for 2 hrs.  Viral pellets were resuspended, separated by 
SDS-PAGE and analysed by Western Blotting using a mouse monoclonal antibody specific to 
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EIAV gp90 (EIAV gp90(A)-86) obtained from NIH AIDS Research and Reference Reagent 
Program (Hussain et al., 1987). 
 
Infection of EMDM 
Six days post isolation, EMDM were transferred to 6-well plates at 2.35×105 cells per 
well and incubated for 24 hrs.  EIAV19 or EIAV17 (containing 30,000 cpm of RT activity in 
0.5 ml) or 0.5 ml of CM was added to each well of EMDM, incubated for 1 hr at 37°C, and 
0.5 ml of fresh complete MEMα was added.  At 0, 0.5, 1, 2, 4, 12, and 24 hpi, EMDM 
were washed with PBS, harvested by trypsinization and pelleted.  EMDM pellets were then 
lysed with Lysis Solution (Ambion) at 1.6×107 cells/ml and stored at -20°C.   
 
RPA 
Cytokine mRNA levels were measured by RPA as previously described (Lim, 2003) 
using the Direct Protect Lysate RPA kit (Ambion, Austin, TX).  Eleven 32P-labeled 
antisense RNA probes specific to equine IL-1α, IL-1β, IL-6, IL-8, IL-10, IL-12 p35, IL-
12 p40, IFN-γ, transforming growth factor-β1 (TGF-β1), TNF-α, and β-actin mRNAs 
were synthesized by in vitro transcription from their respective templates (Lim et al., 
2003a).  Approximately 9×104 cpm of each probes were hybridized with EMDM lysate 
(derived from 2.35×105 cells) overnight and then digested with RNase A/RNase T1 
cocktail.  The protected probe fragments were isopropanol precipitated and resolved on a 
20 cm (length) × 16 cm (width) 5% acrylamide / 8 M urea denaturing gel. The gels were 
dried and exposed to a Fuji Film Imaging Plate (Fuji Photo Co., Ltd., Kanagawa, Japan).  
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Abundance of the protected fragments was quantitated using a Fuji Film Bio-imaging 
Analyzer BAS-1800II Phosphor Imaging System (Fuji Photo Co., Ltd.).  Cytokine 
mRNA levels were calculated based on the photo-stimulated luminescence of the 
cytokine bands, which are directly proportional to the radioactivity, and were normalized 
to the expression levels of β-actin mRNA (expressed as percentage of β-actin mRNA). 
 
Statistical analysis 
Exploratory, descriptive and inferential methods were used to analyze the data.  
Exploratory data analyses included examination of graphical displays of the cytokine 
data by time for each horse.  Descriptive methods included examination of summary 
statistics for various parameters of the cytokine measurements (for example, ratio of 
mean values at fixed time points).  For inferential analyses, linear mixed-effects models 
were fitted using S-PLUS both for comparisons of changes over time among treatments 
(ie, temporal changes) and for comparisons among treatments for a given time (Pinheiro 
and Bates, 2000).  For the linear mixed-effects modeling, an individual animal and each 
replicate within an individual animal were considered as random effects.  For 
comparison of temporal changes, treatment and time were considered as fixed effects.  
For comparisons among treatments for a given time, treatment was considered as a fixed 
effect and data from other times were excluded from the model.  
Data were modeled using a common slope for all horses and random intercepts.  
The assumption that a common slope for all horses was appropriate for a given covariate 
was examined by comparing the likelihood ratio test statistics of a model with differing 
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(random) slopes and intercepts for each horse with a model with a common slope for all 
horses but different intercepts for each horse.  Goodness-of-fit of the models was 
graphically assessed in 3 ways.  First, the standardized residuals were plotted against the 
fitted values.  These plots were examined for outliers and any evidence of a systematic 
pattern, and showed that the residuals were distributed symmetrically around zero with 
an approximately constant variance.  Second, the normal quantile-quantile plot of the 
standardized residuals did not indicate any violations of the normality assumption.  For 
the normality assumption of random effects, we also used a normal quantile-quantile plot 
even if there were only 3 to 4 horses.  The assumptions about the random effects were 
not violated.  Third, the adequacy of the fitted model was better visualized by plotting 
fitted curves with the observed data.  These plots showed that our model fitted well with 
the observed data.  For all analyses, a significance level of P ≤ 0.01 was used.   
 
Results 
 
Characterization of EIAV17 and EIAV19 
To verify the infectivity of the virus stocks and compare the replication of 
EIAV17 and EIAV19, EMDM were infected with EIAV17 or EIAV19 stocks containing 
3000 cpm RT activity or were mock-infected.  Virus replication was monitored by 
measuring RT activity in culture supernatants.  As shown in Fig. 7A, EIAV17 and EIAV19 
replicated to the same levels in EMDM culture.   
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Fig. 7. Characterization of EIAV17 and EIAV19 stocks. (A) Graphical representation 
of EIAV replication in equine monocyte-derived macrophages (EMDM) as monitored 
by culture supernatant reverse transcriptase (RT) activity.  EMDM cultures were 
infected with 3000 cpm of EIAV17 (!) or EIAV19 (!) based on RT activity, or were 
mock infected ("). Aliquots of supernatants were removed from the cultures at 0, 4, 
8 and 12 dpi and assayed for RT activity.  The x-axis indicates time (dpi), and the y-
axis indicates RT activity expressed as cpm/ml. (B) Western blot analysis of EIAV 
SU (gp90). Control media (CM), EIAV17 and EIAV19 stocks (both containing 60,00
cpm of RT activity) were pelleted, separated by 10% SDS-PAGE, electrotransferred
to a nitrocellulose membrane, and probed with a monoclonal antibody specific to 
EIAV SU.  The migration of molecular weight markers (210, 134 and 80 kDa) is 
indicated on the left.  Arrows on the right indicate the SU migration of EIAV17 (top) 
and EIAV19 (bottom).  
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The SU protein contents of EIAV17 and EIAV19 stocks containing equal cpm of 
RT activity were estimated by Western blot analysis using a monoclonal antibody 
specific to a conserved epitope of EIAV SU (Hussain et al., 1987).  The EIAV19 stock 
appeared to contain a higher concentration of SU than the EIAV17 stock (Fig. 7B).  A 
difference in electrophoretic mobility between the SU of the 2 viruses was evident, 
likely due to a difference in their glycosylation since EIAV17 SU has 5 more potential N-
linked glycosylation sites than EIAV19 (Payne et al., 1998).   
 
EIAV17 stimulated expression of IL-1α, IL-1β, IL-6 and TNF-α in EMDM 
Initial experiments were performed to determine the effects of EIAV19 and 
EIAV17 on equine macrophage cytokine expression.  EMDM were cultured for 7 days 
and infected with EIAV19 or EIAV17 or mock-infected with CM.  At 2, 4, 12 and 24 hpi, 
lysates of the infected cells were analyzed with the multi-probe RPA for IL-1α, IL-1β, 
IL-6, IL-8, IL-10, IL-12 p35, IL-12 p40, IFN-γ, TGF-β1, TNF-α, and β-actin mRNA 
expression.   
As shown in the phosphor image of a representative RPA (Fig. 8), IL-1α, IL-1β, 
IL-6 and TNF-α  were expressed at barely detectable levels in CM-treated EMDM, 
whereas TGF-β1, IL-10 and IL-8 mRNAs were readily detected.  IFN-γ, IL12 p35 and 
IL-12 p40 mRNAs were not detected in CM-treated EMDM.  EIAV19 infection induced a 
slight increase of IL-1β mRNA expression at 4 hpi and did not appear to affect the 
expression of other cytokines.  In EMDM exposed to EIAV17, there was a readily  
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Fig. 8. Phosphor image analysis of cytokine expression in EMDM at 2-24 hrs 
post treatment with control media (CM) or infection with EIAV19 or EIAV17.  
In this representative experiment, EMDM derived from donor horse KB were 
harvested at 2, 4, 12 and 24 hpi, and cytokine mRNA levels monitored by
RNAse protection assay (RPA) as described in Materials and Methods.  
Results are presented as individual protected fragments for IL-1α, IL-1β, IL-6, 
IL-8, IL-10, IL-12 p35, IL-12 p40, IFN-γ, TGF-β1, TNF-α and β-actin
separated on a 5% acrylamide/8 M urea denaturing gel and indicated on the 
right. Shown on the left are the positions of the full-length radiolabeled
probes.  
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apparent increase of IL-1α, IL-1β, IL-6 and TNF-α mRNA levels at 2 and 4 hpi.  IL-1β 
mRNA remained elevated up to 12 hrs post EIAV17 infection.   
To confirm these initial observations, the experiment was performed in duplicate 
at 2, 4, 12, and 24 hpi using EMDM derived from 4 different horses (total of 8 
independent measurements).  Cytokine mRNA levels were analyzed by phosphor 
imaging, normalized to the level of β-actin mRNA and expressed as percentage of β-
actin (relative mRNA levels) (Fig. 9).  Since out-bred horses were used, there was 
considerable variation in the levels of cytokine expression by EMDM derived from 
different animals.  Hence, to evaluate the statistical significance of changes in cytokine 
mRNA expression levels, a linear mixed-effect (LME) model was used in which horse-
to-horse variations and variations among duplicate measurements were taken into 
account by considering them as random effects.  Adequacy of the LME models was 
assessed with graphical methods, as described above, and fit of the models was deemed 
appropriate.   
Changes of relative cytokine mRNA levels in EMDM of the 4 horses were 
evaluated by LME modeling and descriptive statistics (Table 6).  At 2 hpi, the mRNA  
levels of IL-1α, IL-1β, IL-6 and TNF-α in EIAV17-infected EMDM were statistically 
higher than those of CM-treated EMDM (p ≤ 0.01).  IL-6 and TNF-α mRNA expression 
remained significantly elevated at 4 hpi in EIAV17-infected EMDM, whereas IL-1α and 
IL-1β returned to that of CM-treated EMDM.  By 12 hpi, mRNA levels of IL-6 and 
TNF-α in EIAV17-infected EMDM were also at the same levels as those in CM-treated 
EMDM.  In contrast, infection of EMDM with EIAV19 did not increase the expression of  
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Fig. 9. Graphical representation of relative cytokine mRNA levels in EMDM derived from 4 horses and 
infected with EIAV17 (!) or EIAV19 (!), or treated with CM ("). The x-axis shows the time (2, 4, 12 and 24
hpi) when cytokine mRNAs in EMDM were measured by RPA, and the y-axis indicates relative mRNA levels 
expressed as a percentage of β-actin mRNA. Identities of the donor horses are shown across the top. To
quantitate the cytokine mRNA levels, radioactivity of the protected cytokine probe were analyzed with a 
phosphor imager and normalized to the β-actin mRNA levels.  Each data point represents the average of 
duplicate measurements (total of 8 analyses per cytokine).
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Table 6 
Comparison of cytokine mRNA levels in EIAV17- or EIAV19-infected EMDM to CM-treated EMDM at 2 to 24 hpi 
  EIAV17 vs. CM EIAV19 vs. CM 
  2 hpi  4 hpi 12 hpi 24 hpi 2 hpi 4 hpi 12 hpi 24 hpi 
Cytokine  Ratioa P value  Ratio P value Ratio P value Ratio P value Ratio P value Ratio P value Ratio P value Ratio P value
IL-1α  2.70b 0.0028  4.04 0.0107 1.04 0.7168 0.68 0.0242 0.74 0.5891 1.34 0.7441 0.62 0.0059 0.55 0.0027
IL-1β  4.40 0.0006  9.08 0.0153 1.35 0.2209 0.57 0.0192 1.05 0.9446 1.90 0.7642 0.50 0.0843 0.30 0.0007
IL-6  1.61 0.0011  2.62 0.0033 0.88 0.2232 0.57 0.0414 0.67 0.0470 0.89 0.8154 0.55 0.0003 0.30 0.0211
IL-8  0.98 0.8639  1.00 0.9669 0.66 0.0035 0.72 0.0849 0.73 0.0277 0.71 0.0277 0.53 0.0003 0.70 0.0655
IL-10  1.26 0.1592  1.39 0.0851 0.66 0.0108 0.75 0.1815 0.86 0.4336 0.80 0.3427 0.60 0.0038 0.67 0.0805
TGF-β1  1.16 0.0378  1.07 0.1715 1.00 0.9723 0.65 0.0891 1.07 0.3239 1.07 0.1532 0.84 0.0257 0.60 0.0030
TNF-α  1.72 0.0028  1.94 0.0042 0.87 0.1625 0.82 0.0622 0.93 0.7182 1.11 0.7081 0.76 0.0180 0.65 0.0395
a Ratios of cytokine mRNA levels in EIAV17- or EIAV19- infected EMDM over cytokine mRNA levels in CM-treated 
EMDM were derived from linear mixed-effect models. 
b Bold face indicates that cytokine mRNA level is significantly increased above the CM level (p < 0.01). 
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any cytokine when compared to CM treatment (Table 6).  A slight but significant (p ≤ 
0.01) decrease of IL-1α, IL-1β, IL-6, IL-8, IL-10 and TGF-β1 mRNA levels was 
observed in EMDM at 12 to 24 hrs after EIAV19 infection.  IFN-γ, IL-12 p35 and IL-12 
p40 mRNAs were not detected in EMDM exposed to CM, EIAV17 or EIAV19 (data not 
shown). 
 
Kinetics of cytokine mRNA levels at 0 to 4 hpi 
Since the modulation of cytokine expression only occurred during the early 
stages of infection (2 and 4 hpi) and was absent at the late stages (12 and 24 hpi), we 
investigated the response of these cytokine genes to EIAV infection at early times in 
more detail.  EMDM were treated with CM, EIAV19 or EIAV17, and cytokine mRNA 
levels were measured at 0.5, 1, 2 and 4 hpi.  In these experiments, cytokine mRNA 
levels were also measured in EMDM prior to addition of EIAV or CM to establish the 
mRNA expression profile of the tested cytokines in untreated EMDM (considered 
equivalent to 0 hpi).   
The phosphor image of a representative RPA revealed that the mRNA levels of IL-
1α, IL-1β, IL-6, TGF-β1 and TNF-α mRNAs in CM-treated EMDM were similar to 
those in untreated EMDM (0 hpi), whereas mRNA levels of IL-8 and IL-10 appear to 
vary over time following CM treatment (Fig. 10).  The representative RPA indicated IL-
1α, IL-1β, IL-6, IL-8, IL-10 and TNF-α mRNA levels were increased in EIAV17-infected 
EMDM as early as 0.5 hpi and 1 hpi.  At 4 hpi, IL-1α, IL-1β and IL-6 mRNAs remained 
elevated in EIAV17-infected cells.  There were no apparent alterations of TGF-β1 mRNA in  
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Fig. 10.  Phosphor image showing a representative experiment of early cytokine
mRNA expression in EMDM treated with CM or infected with EIAV19 or EIAV17 at 
0.5 to 4 hpi.  EMDM derived from donor horse 2025 were cultured for 7 days, 
treated with CM (left panel) or infected with EIAV19 (center panel) or EIAV17 (right 
panel), and harvested at 0.5, 1, 2, and 4 hpi. Lysates derived from 2.35×105 EMDM 
were analyzed for IL-1α, IL-1β, IL-6, IL-8, IL-10, IL-12 p35, IL-12 p40, IFN-γ, 
TGF-β1, TNF-α and β-actin mRNA expression by RPA. Shown on the left are the 
positions of the full-length radiolabeled probes. Indicated on the right are positions 
of the individual protected fragments.  
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EIAV17-infected EMDM.  As previously noted and in contrast to EIAV17, EIAV19 infection 
failed to affect cytokine expression in EMDM.  mRNAs of IFN-γ, IL-12 p35 and IL-12 
p40 were undetected in CM-treated EMDM and were not induced by EIAV17 or EIAV19 
infection at any of the tested times.   
To ensure reproducibility, the experiment was repeated in duplicate using 
EMDM derived from peripheral blood of 3 different horse donors (total of 6 independent 
measurements).  Fig. 11 shows the quantitative results of these experiments with the  
cytokine mRNA levels normalized to the β-actin mRNA level.  These graphical 
representations also illustrate that the effects of EIAV infection and CM treatment on 
cytokines were consistent, but the relative mRNA levels were variable among EMDM of 
different animals (Fig. 11).  Therefore, statistical significance of the changes in cytokine 
mRNA levels was determined by LME modeling as described and is summarized in 
Table 7.  Statistical analyses of results from EMDM of 3 horses confirmed that there 
were no significant differences in IL-1α (p = 0.5362), IL-1β (p = 0.2239), IL-10 (p = 
0.3425), TGF-β1 (p = 0.9257) or TNF-α (p = 0.7205) mRNA level between CM-treated 
and untreated EMDM (data not shown).  IL-6 and IL-8 mRNA expression was 
significantly altered by CM treatment (p = 0.0019 and p = 0.0008, respectively).   
In EIAV17-infected EMDM, significant elevations of IL-1α and IL-1β expression 
were detected as early as 0.5 hpi and peaked at 1 hpi (Table 7).  IL-1α and IL-1β mRNA 
levels in EIAV17-infected EMDM were 8.7-fold and 6.2-fold, respectively, higher than those 
in CM-treated EMDM.  At 2 and 4 hpi, IL-1α and IL-1β mRNA levels in EIAV17-infected 
EMDM were still significantly higher (2.8-fold to 5.5-fold) than those in CM-treated EMDM.   
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Fig. 11. Graphical representation of the relative cytokine mRNA levels induced early (0.5 to 4 
hrs) by EIAV17 (!) or EIAV19 (!) infection, or CM (") treatment in EMDM derived from 3 
horses. The x-axis shows the time (hpi) when cytokine mRNAs in EMDM were analyzed by 
RPA and the y-axis indicates relative mRNA levels (expressed as a percentage of β-actin 
mRNA).  To quantitate the cytokine mRNA levels, radioactivity of the protected cytokine 
probe were analyzed with a phosphor imager and normalized to the β-actin mRNA levels.  
Identities of the donor horses are indicated across the top.  Each data point represents the 
average of duplicate measurements.
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Table 7 
Comparison of cytokine mRNA levels in EIAV17- or EIAV19-infected EMDM to CM-treated EMDM at 0.5 to 4 hpi 
  EIAV17 vs. CM EIAV19 vs. CM 
  0.5 hpi  1 hpi 2 hpi 4 hpi 0.5 hpi 1 hpi 2 hpi 4 hpi 
Cytokine  Ratioa P value  Ratio P value Ratio P value Ratio P value Ratio P value Ratio P value Ratio P value Ratio P value
IL-1α  4.12b 0.0025  8.68 0.0001 5.46 <0.0001 3.03 <0.0001 1.12 0.8786 1.98 0.4464 1.42 0.4762 1.60 0.0580
IL-1β  2.69 0.0006  6.21 <0.0001 5.51  0.0001 2.76 0.0003 1.06 0.8601 1.89 0.2298 1.70 0.2962 1.39 0.2522
IL-6  1.35 0.0844  1.31 0.0050 1.77  0.0001 1.66 0.0428 0.93 0.7154 1.03 0.7400 0.96 0.7135 0.85 0.6148
IL-8  1.11 0.2899  1.35 0.0006 1.09 0.1840 0.83 0.0052 0.89 0.3120 1.02 0.7997 0.81 0.0160 0.73 0.0002
IL-10  1.87 0.0004  2.05 0.0001 1.71 0.0015 1.00 0.9774 1.34 0.0727 1.26 0.1328 0.90 0.5458 0.80 0.0374
TGF-β1  0.99 0.8305  1.05 0.2512 1.24 0.0171 1.32 0.0259 0.96 0.5336 0.99 0.7365 1.08 0.3712 1.07 0.5912
TNF-α  5.74 0.0052  5.79 0.0082 2.15 0.0079 1.93 0.0063 1.27 0.8433 1.31 0.8348 1.02 0.9630 0.99 0.9769
a Ratios of cytokine mRNA levels in EIAV17- or EIAV19- infected EMDM over cytokine mRNA levels in CM-treated 
EMDM were derived from linear mixed-effect models. 
b Bold face indicates that cytokine mRNA expression is significantly increased above the CM level (p < 0.01). 
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In contrast, IL-1α and IL-1β mRNA expression was only slightly increased (approximately 2-
fold above CM) at 0.5 to 4 hpi in EIAV19-infected EMDM, but the differences were not 
statistically significant (Table 7).  EIAV17-infected EMDM consistently expressed 
significantly higher levels of IL-1α and IL-1β mRNAs than EIAV19-infected EMDM at all of 
the time points tested (data not shown). 
Although an increase of IL-6 mRNA level was detected in EIAV17-infected EMDM at 
0.5 hpi (Fig. 10), the difference was not significant when compared to CM-treated EMDM 
until 1 and 2 hpi (Table 7).  At 4 hpi, IL-6 mRNA level still appeared to be increased in 
EIAV17-infected EMDM when compared to CM-treated EMDM, but again the levels were not 
significantly elevated.  EIAV17-induced IL-6 expression only reached 1.8-fold above CM, 
even at the peak level (2 hpi).  Nonetheless, it is noteworthy that the EIAV17-induced 
upregulation of IL-6 mRNA was significantly higher at 1 and 2 hpi when compared to CM 
treatment, which itself has an upregulating effect on IL-6 mRNA expression.  In EIAV19-
infected EMDM, IL-6 mRNA level was not significantly different from that in the CM-treated 
EMDM at any time point (Table 7). 
IL-8 mRNA expression was significantly increased in EIAV17-infected EMDM 
at 1 hpi (Table 7).  However, since IL-8 mRNA expression was also significantly 
increased in CM-treated EMDM at 4 hpi, we were unable to determine whether the 
upregulation of this gene in EIAV17-infected EMDM was infection-specific.  IL-8 
mRNA expression in EIAV19-infected EMDM also fluctuated but never significantly 
varied from CM levels.  
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IL-10 mRNA was significantly increased by EIAV17 at 0.5 hpi, peaked at 1 hpi (2-fold 
increase compared to CM), and remained significantly higher than that of the CM-treated 
EMDM through 2 hpi (Table 7).  At 4 hpi, EIAV17-induced IL-10 expression decreased such 
that the mRNA level was no longer significantly different from that of CM treatment.  The 
early and transient elevation of IL-10 mRNA expression was absent in EIAV19-infected 
EMDM.   
TGF-β1 mRNA was constitutively expressed in CM-treated EMDM and was not 
affected by infection with either EIAV17 or EIAV19 (Table 7). 
The highest levels of TNF-α mRNA were detected in EIAV17-infected EMDM at 0.5 
and 1 hpi (Fig. 10).  Although the mRNA levels decreased over time, EIAV17-infected 
EMDM continued to express significantly more TNF-α mRNA than CM-treated EMDM, 
while EIAV19 infection did not affect TNF-α mRNA expression (Table 7).   
Taken together, these data show that there is a clear distinction between the 
virulent EIAV17 and the avirulent EIAV19 in their effects on EMDM cytokines.  These 
differential effects on cytokine expression correlated with the virulence of the 2 
molecularly cloned viruses.  EIAV17 infection of EMDM increased the levels of IL-1α, 
IL-1β, IL-6, IL-10 and TNF-α mRNAs, whereas EIAV19 had no effect on any of the 
cytokines tested.  EIAV17-induced cytokine expression occurred early (0.5 to 4 hrs) after 
infection and abated by 12 hpi.   
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Discussion 
This detailed study of cytokine induction by EIAV is enhanced by the used of 
EMDM, the natural host cells for EIAV, and the well-characterized, biologically distinct 
EIAV stocks.  EIAV17 is a chimeric virus contructed by substituting the LTR and env/rev 
regions of EIAV19 with those derived from the consensus sequence of the highly virulent 
EIAVWyo (Payne et al., 1998).  EIAV17 and EIAV19 share common gag, pol, tat, S2 and 
the amino terminus of env, which consists of the first 89 amino acids of the env open 
reading frame and the first coding exon of rev (Payne et al., 1998).  The most remarkable 
differences between EIAV17 and EIAV19 are found in 2 regions of SU previously 
identified as the primary neutralizing domain (PND) and the hypervariable domain.  The 
PND region of EIAV SU is proposed to be functionally analogous to the V3 loop of 
HIV-1 SU, known to be important for macrophage/T cell tropism and receptor-mediated 
fusion (Ball et al., 1992).  In vivo, experimental infection of Shetland ponies with 
EIAV17 causes fatal acute symptoms including sustained febrile episodes and profound 
thrombocytopenia (Payne et al., 1998).  Although EIAV19 replicates and causes 
seroconversion in infected Shetland ponies, it fails to cause disease.  Since both EIAV17 
and EIAV19 replicate to high titer in primary horse macrophages in vitro, the distinct 
clinical manifestations of the 2 clones likely are not attributed to differential levels of 
viral expression, but changes in other aspects of the virus-host cell interaction (Payne et 
al., 1998; Payne et al., 1994; Payne et al., 1994).   
To our knowledge, this is the first study to investigate the cytokine profiles in 
equine macrophages infected with EIAV derived from molecular clones.  We 
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demonstrated that in vitro infection of EMDM with a stock of the highly virulent EIAV17 
upregulated mRNA expression of IL-1α, IL-1β, IL-6, IL-10 and TNF-α.  Significant 
induction of these cytokine mRNAs was detected as early as 0.5 to 1 hr after EIAV17 
infection.  The expression of these cytokines remained elevated for up to 4 hpi and 
returned to control levels thereafter.  In contrast, EMDM infected with a stock of the 
avirulent EIAV19 either showed no effects or slightly decreased cytokine expression.   
Only one previous study has investigated the production of cytokines by equine 
macrophages in vitro in response to EIAV infection (Swardson et al., 1997).  This study 
showed an in vitro infection of bone marrow derived macrophages (BMDM) with the 
mildly virulent, cell culture-adapted WSU5 strain of EIAV (EIAVWSU5)  increases IL-6 
activity in culture media, which agrees with the findings of the present study.  Increased 
IL-6 activity is also detected in serum of ponies experimentally infected with EIAVWyo 
(Sellon et al., 1999).  TNF-α activity is elevated in EIAVWyo -infected Arabian foals, 
EIAVWSU5-infected SCID foals (Tornquist et al., 1997) and ponies infected with PR and 
PV strains of EIAV (EIAVPR and EIAVPV, respectively )(Costa et al., 1997).  However, 
increase of TNF-α production was not detected in EIAVWSU5-infected BMDM culture, 
which may due to the differences in strains of EIAV and/or sources of macrophages 
(Swardson et al., 1997).  Finally, TGF-β (isoform unknown) and IFN-α levels are 
upregulated in plasma and bone marrow of EIAV-infected foals (Tornquist et al., 1997).  
As our data failed to detect an increase of TGF-β1 expression in EMDM infected in vitro 
by either EIAV strain, TGF-β in the infected horse may represent other TGF-β isoforms 
(TGF-β2 and TGF-β3) or TGF-β1 produced by other cells.  Moreover, TGF-β 
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production by macrophages is often regulated by activation of the latent molecules 
instead of transcription of the gene (Toossi et al., 1995).   
Macrophages are major targets for infection of other lentiviruses and have been 
evaluated for cytokine induction.  In vitro infection of human monocyte-derived 
macrophages by HIV-1 increases both mRNA expression and protein production of IL-1 
and TNF-α (Herbein et al., 1994; Merrill et al., 1989).  Elevated levels of IL-6 are found 
in monocytes derived from HIV-positive donors and are induced by in vitro infection of 
monocytes with HIV-1 (Breen et al., 1990; Nakajima et al., 1989).  However, some 
investigators report contradictory findings wherein pro-inflammatory cytokines are not 
induced by HIV infection of macrophages (Molina et al., 1990).  Variations such as HIV 
isolate, macrophage culture methodology and time at which cytokines are analyzed 
could contribute to the discrepant results.  Likewise, FIV infection causes elevation of 
IL-6 and TNF-α in feline alveolar macrophage (Ritchey et al., 2001). Microglial cells 
isolated from rhesus monkeys acutely infected with SIVmac produce increased levels of 
IL-1β, IL-6 and TNF-α, whereas cytokine production by peripheral macrophages is not 
altered (Sopper et al., 1996).  Primary ovine microglial cultures infected with MVV also 
express elevated levels of IL-6 and TNF-α but not IL-1β (Ebrahimi et al., 2000).  In 
contrast, CAEV infection of primary macrophage culture has suppressive effects on IL-
1β, IL-6 and TNF-α expression (Lechner et al., 1997).  In summary, upregulation of IL-
1α/β, IL-6 and TNF-α expression appears to be a common outcome of lentivirus-
infected macrophages with the exception of CAEV.   
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One of the most notable aspects of the current study is the differential effects of 
EIAV17 and EIAV19 on cytokine expression correlate with their ability to cause severe 
disease.  Such correlation is also observed in ponies infected with the virulent EIAVPV 
and the avirulent EIAVPR, where higher levels of TNF-α is detected in sera of EIAVPV-
infected ponies than that of EIAVPR-infected ponies (Costa et al., 1997).  In addition, the 
levels of serum TNF-α positively correlate with viremia, severity of clinical signs and 
vaccine-induced disease enhancement, suggesting a pathogenic role of TNF-α in acute 
EIA (Costa et al., 1997).  Correlation between cytokine gene expression and viral 
pathogenicity has been reported in other lentiviral models.  For example, monkeys 
acutely infected with the virulent SIVmac express higher levels of IL-1β, IL-6 and TNF-
α in lymph nodes and PBMC than those infected with the avirulent derivatives of 
SIVmac (Zou et al., 1997; Benveniste et al., 1998).  Therefore, we hypothesize that the 
propensity of EIAV17 to upregulate macrophage cytokines contributes, at least in part, to 
the disease outcome of EIAV17 infection.   
IL-1α, IL-1β, IL-6 and TNF-α are pro-inflammatory cytokines predominantly 
produced by macrophages (Murtaugh et al., 1996).  IL-1 has a plethora of local and 
systemic biologic activities, most of which are achieved through modulating expression 
of the biologically active molecules within and outside the immune system (Dinarello, 
1996).  For example, IL-1 causes fever, anorexia and lethargy, common symptoms of 
EIA, by inducing expression of prostanglandins (Dinarello, 1996).  IL-1 also induces 
expression of other cytokines, including IL-6 and TNF-α.   
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Biological effects of TNF-α are dose dependent, with high doses inducing shock, 
tissue injury, vascular leakage, hypoxia and other pathological features identical to septic 
shock.  Prolonged exposure to low doses of TNF-α causes cachexia (Tracey and Cerami, 
1994).  The inflammatory effects of TNF-α are similar to those of IL-1.  An abridged list 
of these effects includes migration of leukocytes, activation of endothelial cells and 
stimulation of the hypothalamic pituitary axis (HPA) (Tracey and Cerami, 1994).   
Although IL-6 shares many functions of IL-1 and TNF-α, the induction of the 
acute phase response is the most prominent IL-6 activity in vivo, which downregulates 
certain aspects of the inflammatory response, including inhibition of IL-1 and TNF-α 
production (Gadient and Patterson, 1999).  IL-6 is regarded as a B cell proliferation and 
differentiation factor due to its ability to promote immunoglobulin (Ig) secretion in vivo 
(Jego et al., 2001).  IL-6 also participates in regulating various steps of hematopoiesis in 
vivo and is a potent cofactor of hematopoietic progenitor cells in vitro (Heike and 
Nakahata, 2002).   
Proinflammatory cytokines (IL-1, IL-6 and TNF-α) are well-known for their 
pyrogenic activities (Dinarello, 1999).  In addition to fever, these cytokines cause 
anorexia and hypermetabolism, leading to the wasting diseases commonly seen in HIV 
AIDS (Chang et al., 1998).  Fever, anorexia and wasting also are common clinical signs 
of acute and chronic EIA and characteristically coincide with viremia (Montelaro et al., 
1993), suggesting pro-inflammatory cytokines may play a role in EIA pathogenesis.  
A correlation between elevation of plasma TNF-α levels and severity of anemia 
is found in ponies experimentally infected with EIAV (Costa et al., 1997).  IL-1 and 
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TNF-α may exacerbate EIA anemia by activating macrophages and neutrophils, 
enhancing phagocytosis of complement-coated erythrocytes and may suppress 
erythropoiesis by downregulating erythropoietin production and dysregulating iron 
metabolism (Means, 1997; Means, 2000), both shown to contribute to EIA anemia 
(Sellon et al., 1994; Sentsui and Kono, 1987a; Sentsui and Kono, 1987b; Swardson et 
al., 1992). 
There is accruing evidence for roles of cytokines in mechanisms of EIA-
associated thrombocytopenia.  Elevated levels of TNF-α, TGF-β and IFN-α are found in 
the plasma and bone marrow of EIAV-infected immunocompetent and SCID foals 
during and prior to the onset of thrombocytopenia (Tornquist et al., 1997).  The pre-
thrombocytopenic plasma has suppressive effects on proliferation of megakaryocyte 
colonies in culture, which are at least partially attributed to activities of TNF-α and 
TGF-β (Tornquist and Crawford, 1997).  Human recombinant TNF-α has suppressive 
effects on megakaryocyte colonies in vitro (Lu et al., 2000).  In addition to suppressing 
production of platelets, injection of purified TNF-α induces severe thrombocytopenia in 
mice and humans possibly by stimulating secretion of platelet agonists (Michelmann et 
al., 1997; Tacchini-Cottier et al., 1998).  Other studies show that IL-1 and IL-6 are 
capable of directly activating platelets in vitro (Oleksowicz et al., 1994; Bar et al., 1997).  
In vivo platelet activation is observed in thrombocytopenic ponies acutely infected with 
EIAVWyo, such that the accelerated removal of activated platelets may contribute to the 
net decrease of platelet in circulation (Russell et al., 1999).   
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IL-10, also induced by EIAV17, is regarded as an anti-inflammatory cytokine that 
downregulates the inflammatory reaction by inhibiting production of pro-inflammatory 
cytokines and bioactive prostaglandins (Moore et al., 2001).  IL-10 also inhibits the 
antigen-presentation capabilities of monocytes/macrophages.   
IL-10 and IL-6 enhance various B cell functions and increase total serum 
globulin and IgM concentrations, which are commonly seen in EIAV-infected horses 
(Sellon et al., 1994; Sellon et al., 1999; Russell et al., 1998).  Polyclonal B cell activation 
by IL-6 and IL-10 may exacerbate some of the chronic EIA pathological features 
mediated by immune complexes, including hemolytic anemia, glomerulitis and hepatitis 
(Swardson et al., 1997).  Although antibody-mediated enhancement of EIAV infection 
has not been directly demonstrated, vaccination of ponies with either p26 or go90 
resulted in enhanced viral replication and disease severity following challenge with 
heterologous pathogenic strains of EIAV(Issel et al., 1992; Costa et al., 1997).  These 
data suggest a detrimental effect of non-neutralizing antibodies.   
The cytokine-inductive properties of EIAV17 may also affect EIAV disease 
outcome by modulating viral replication.  In HIV infection, IL-1α, IL-1β, IL-6 and TNF-
α are among the cytokines best known to upregulate HIV replication in monocyte-
derived macrophages and monocytic cells lines, enhancing HIV expression at the 
transcriptional (TNF-α) or post-transcriptional (IL-1α, IL-1β and IL-6) level (Fauci, 
1996).  The concept that cytokines induced by HIV-1 infection of macrophages could in 
turn modulate viral  replication may also apply to EIAV.  In experimentally infected 
Shetland ponies, EIAV17 replicates to higher levels than EIAV19, however the two viruses 
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replicate with comparable efficiencies in EMDM culture.  We speculate that induction of 
the pro-inflammatory cytokines IL-6 and TNF-α contributes to the enhanced replication 
of EIAV17 in vivo.  This hypothesis is supported by the positive correlation of IL-6 and 
TNF-α serum levels with EIAV viremia in experimentally infected ponies (Sellon et al., 
1999; Costa et al., 1997).   
Cytokine mRNAs stimulated by EIAV17 were expressed shortly after infection of 
EMDM.  The kinetics of IL-1 and TNF-α mRNA upregulation by EIAV17 is remarkably 
similar to that observed in HIV-1 infection (Herbein et al., 1994),  whereby the rapidity 
of the cytokine response is due to HIV-1 Env binding to its receptor (CD4) on the 
macrophage surface (Chirmule and Pahwa, 1996).  To date, the identity of receptor(s) 
for EIAV infection is unclear, however the rapid induction of cytokine mRNAs suggests 
that interactions between EIAV Env and macrophage surface molecules are sufficient to 
stimulate cytokine expression.  Given the marked differences in env sequence between 
EIAV17 and EIAV19, it is conceivable that the differential effects on cytokine expression 
are due to differential Env binding and activation of surface molecule(s).  EIAV17 and 
EIAV19 also have distinct Rev proteins and LTR sequences, but it is highly unlikely 
either of these regions impact events that occur within 0.5 to 4 hrs after EIAV infection 
of EMDM.   
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CHAPTER IV 
 
INDUCTION OF EQUINE MACROPHAGE CYTOKINES BY THE VIRULENT 
MOLECULARLY CLONED EQUINE INFECTIOUS ANEMIA VIRUS (EIAV17) 
IS INDEPENDENT OF VIRAL REPLICATION 
 
p19/wenv17 is a virulent EIAV molecular clone generated by replacing the LTR, env 
and rev of the avirulent EIAV clone pSPeiav19 with sequences derived from the 
Wyoming field strain EIAV (EIAVWyo) (Payne et al., 1998).  We previously 
demonstrated infection of equine monocyte-derived macrophages (EMDM) by virus 
derived from p19/wenv17 (EIAV17) causes an increase of IL-1α, IL-1β, IL-6, IL-10 and 
TNF-α mRNA expression (Lim et al., 2003b).  In contrast, the virus derived from 
pSPeiav19 (EIAV19) fails to stimulate cytokine expression in cultured equine macrophages.  
Since both viruses replicate to similar levels in EMDM cultures, their differential effects on 
cytokine expression are not simply due to differences in viral loads (Lim et al., 2003b).   
The goal of this study is to begin to elucidate mechanisms by which EIAV17 induces 
cytokine expression.  The rapid induction (0.5 to 4 hrs post-infection, hpi) of cytokine 
expression in EIAV17-infected EMDM suggests that cytokines are stimulated by early 
events following exposure of the virus to the macrophages (Lim et al., 2003b).  Since 
binding of the viral Env glycoprotein to cell surface molecules comprises the earliest 
interaction between a retrovirus and its host cell (Hunter, 1997), we hypothesized that 
EIAV17 induces cytokines by binding to surface molecules of equine macrophages.   
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In support of this hypothesis, the most remarkable sequence differences between 
EIAV17 and EIAV19 are found in the Env protein (Payne et al., 1998).  The divergence in 
Env may affect the interactions of the 2 viruses with macrophage surface molecules and 
lead to their differential effects on cytokine expression.  Although sequence differences 
are also found in the Rev proteins and U3 regions of EIAV17 and EIAV19, they are 
unlikely to affect the early events of viral infection (Payne et al., 1998).  To further 
demonstrate that cytokine induction is mediated by EIAV17 binding, we exposed EMDM 
to UV-inactivated EIAV17 (UV-EIAV17) and monitored cytokine induction to test if viral 
replication is required for upregulation of cytokines.  
EMDM cultures were established from peripheral blood of EIA-negative donor 
horses as previously described (Lim et al., 2003b).  EMDM cultures were utilized to 
amplify EIAV17 generated from p19/wenv17-transfected D17 cells (canine lung 
osteosarcoma, ATCC CCL-183).  The amplified EIAV17 were ultra-filtered as previously 
described (Lim et al., 2003b).  Supernatants of mock-infected EMDM (termed control 
media, CM) were collected, ultra-filtered under the same conditions and served as the 
negative control.   
For UV irradiation, 6 ml of EIAV17 or CM were layered in a 150×25mm petri dish 
and kept on ice.  The open dish was exposed to a 1330 mW/cc UV bulb at a 15cm 
distance for 30 min with agitation every 10 min.  The effects of UV irradiation on 
EIAV17 infectivity were determined by comparing the growth of EIAV17 and UV-EIAV17 
in EMDM cultures.  EMDM were exposed to UV-EIAV17 stock containing 3000 cpm of 
reverse transcriptase (RT) activity or were mock-infected with UV-irradiated CM (UV-
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CM), and virus replication was monitored by measuring the RT activity in culture 
supernatants.  As expected, culture supernatants of EIAV17-infected EMDM showed a 
steady increase of RT activity from 4 to 12 days post-infection (dpi), indicating 
production and release of virions (Fig. 12).  In contrast, there was no increase of RT 
activity in supernatants of EMDM cultures exposed to UV-EIAV17 or UV-CM.  These 
results confirm that the UV irradiation protocol employed was sufficient to block the 
replication of EIAV17 in EMDM. 
The replication-defective UV-EIAV17 was then tested for its effects on IL-1α, IL-
1β, IL-6, IL-10 and TNF-α mRNA expression in EMDM, since our previous study 
shows that EIAV17 induces elevation of these cytokines (Lim et al., 2003b).  EMDM 
cultured for 6 days were transferred to 6-well plates at 2.35×105 cells per well.  Twenty-
four hrs later, each well of EMDM was exposed to 0.5 ml of UV-EIAV17 (containing 
30,000 cpm of RT activity) or UV-CM.  EMDM cytokine mRNA levels at 0, 0.5, 1, 2 and 
4 hrs post exposure (hpe) was analyzed by multi-probe RPA using radiolabeled RNA 
probes specific to equine cytokine genes followed by phosphor imaging (Lim et al., 
2003a).   
Fig. 13 shows representative data from an experiment performed using EMDM 
derived from a single donor horse.  Each treatment was replicated in 3 separate wells of 
EMDM.  The relative cytokine mRNA level at each time point represent the mean ± 
standard error (SE) of 3 parallel measurements.  Significant differences between 
treatments were determined with 2-tailed Student’s t test.  P < 0.05 was considered  
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Fig. 12. Graphical representation of RT activities in EIAV-
infected EMDM culture supernatants.  EMDM cultures were 
infected with 3000 cpm of EIAV17 (!) or UV-EIAV17 (") or 
mock-infected (!). Aliquots of supernatants were removed from 
the cultures at 0, 4, 8 and 12 dpi and analyzed by RT activity 
assay.  The x-axis indicates time, and the y-axis indicates RT 
activity expressed as cpm/ml.  
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Fig. 13. Graphical representation of relative cytokine mRNA levels in EMDM exposed to UV-EIAV17.  
EMDM were exposed to UV-EIAV17 (!) or UV-CM (!), and cytokine expression was analyzed with 
RPA at 0, 0.5, 1, 2 and 4 hrs after exposure. To quantitate cytokine mRNA levels, the radioactivity of 
the protected cytokine probe were analyzed with a phosporimager and normalized to the β-actin mRNA
levels.  The x-axis indicates the time when cytokine mRNAs in EMDM were analyzed (hrs post 
exposure), and the y-axis indicates relative mRNA levels (expressed as a percentage of β-actin).  Each 
data point represents the means ± SE of triplicate measurements.  Asterisks (∗) indicate significant 
differences (p < 0.05) between EMDM exposed to UV-EIAV17 and UV-CM.  Pound signs (#) indicate 
significant differences (p < 0.05) between EMDM exposed to UV-CM and untreated EMDM (0 hpe). 
 
 
92
 
 
93
significantly different.  The results described below were reproduced in experiments 
performed using EMDM derived from 3 other horses.   
In untreated EMDM (0 hpe), IL-1α, IL-1β, IL-6, IL-10 and TNF-α mRNAs were 
expressed at barely detectable levels (Fig. 13).  Exposure to UV-CM did not affect the 
expression levels of IL-1α, IL-1β and IL-6 at any of the tested time points (Fig. 13).  IL-
10 and TNF-α expression slightly but significantly (p < 0.05) increased at 1 hpe of 
EMDM to UV-CM.  These 2 cytokines were not affected by UV-CM at other time 
points.  A slight increase of IL-10 expression was observed in CM-treated EMDM in our 
previous study (Lim et al., 2003b).  The reason for TNF-α induction in EMDM exposed 
to UV-CM is unclear. 
In EMDM exposed to UV-EIAV17, IL-1β and TNF-α expression was 
significantly increased as early as 0.5 hpe when compared to UV-CM treatment (Fig. 
13).  IL-1β expression in EMDM exposed to UV-EIAV17 peaked at 1 hpe (12-fold above 
UV-CM level) and returned to basal level at 4 hpe.  TNF-α expression in UV-EIAV17-
treated EMDM remained significantly elevated at 1 hpe.  At 2 hpe, the mean TNF-α 
mRNA level did not decrease in UV-EIAV17-exposed EMDM but was not significantly 
different (p = 0.1043) from that of UV-CM treatment, likely due to the large variance of 
UV-EIAV17-induced TNF-α expression (Fig. 13). 
IL-1α and IL-6 mRNA levels in EMDM were significantly elevated (4.1-fold 
and 2.5-fold above UV-CM levels, respectively) at 1 hpe to UV-EIAV17 (Fig. 13).  IL-1α 
expression remained significantly elevated through 2 hpe and returned to basal level by 4 
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hpe.  Although IL-6 expression in EMDM exposed to UV-EIAV17 was noticeably higher 
than that in UV-CM-treated EMDM at 2 hpe, the difference was not significantly 
different.  Again, this is likely due to the large variance of UV-EIAV17-induced IL-6 
expression at this time point (Fig. 13).   
IL-10 appeared to increase in EMDM exposed to UV-EIAV17 for 0.5-2 hrs (Fig. 
13).  However statistical analysis revealed that the increase was significant only at 2 hpe.  
Although IL-10 expression peaked at 1 hpe to UV-EIAV17, the increase was not 
significant due to the concomitant increase of IL-10 expression in UV-CM-treated 
EMDM (Fig. 13). 
In summary, exposure of EMDM to UV-EIAV17 resulted in increased expression 
of IL-1α, IL-1β, IL-6, IL-10 and TNF-α, the cytokines shown stimulated by EIAV17 
infection (Lim et al., 2003b).  IL-1α, IL-1β, IL-6, and TNF-α were rapidly induced 
within 0.5 to 1 hpe to UV-EIAV17, akin to the kinetics of EIAV17-induced cytokine 
expression (Lim et al., 2003b).  Since UV-EIAV17 is unable to replicate in EMDM, these 
results indicate that viral replication is not required for induction of cytokines by EIAV17.  
In addition, UV irradiation does not affect binding of HIV-1 to target cells (Henderson et 
al., 1992).  Taken together, these show that EIAV17 activation of cytokine gene 
expression is replication-independent and suggest binding of EIAV17 to equine 
macrophage surface molecules is sufficient.   
It is well established that binding of HIV-1 Env to the CD4 cellular receptor 
induces expression of a plethora of host-cell genes including various cytokines and 
chemokines (Chirmule and Pahwa, 1996; Cicala et al., 2002).  IL-1, IL-6, IL-10 and 
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TNF-α are among the cytokines that are induced by binding of HIV-1 Env to human 
macrophages (Nakajima et al., 1989; Herbein et al., 1994; Merrill et al., 1989; Akridge 
et al., 1994).  Remarkably, the kinetics of cytokine induction by HIV-1 binding bears 
striking resemblance to that of EIAV17 and UV-EIAV17.  For example, IL-1β and TNF-α 
mRNA levels increase in human macrophages within 0.5-3 hrs after HIV-1 infection and 
decrease to control levels thereafter (Herbein et al., 1994).  Similarly, elevation of IL-10 
mRNA in human macrophages is detected as early as 3 hpe to HIV-1 (Akridge et al., 
1994).  In agreement with our observation, blocking HIV-1 replication by heat-
inactivation or β-propiolactone does not affect the induction of IL-1, IL-6 and TNF-α by 
HIV-1 binding (Nakajima et al., 1989; Merrill et al., 1989).   
While the transmembrane (TM) region of HIV-1 Env induces some cytokines, 
most of the Env-mediated cytokine activation are the results of CD4 receptor binding by 
hte SU region (gp120) (Koka et al., 1995; Cicala et al., 2002; Chirmule and Pahwa, 
1996).  Binding of HIV-1 SU to CD4 transduces intracellular signaling events that 
activate the transcription factors regulating cytokine expression.  A study using truncated 
proteins and synthetic peptides of HIV-1 SU shows that many different regions of HIV-1 
SU induce cytokines (Koka et al., 1995).  Among these regions, the third variable 
domain (termed the V3 loop), which is a major determinant of cell tropism and 
coreceptor usage, is consistently identified as the critical domain for induction of 
cytokines in different cell types (Ankel et al., 1994; Koka et al., 1995; Khanna et al., 
2000).   
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In support of the concept that induction of cytokines is mediated by EIAV17 
binding, the most remarkable differences between EIAV17 and EIAV19 are found within 
SU (31 out of 443 amino acids, or 7.0%) (Payne et al., 1998).  In addition, the divergent 
amino acids are concentrated in 2 previously identified variable domains of SU (Payne et 
al., 1998).  One of these regions is termed the principal neutralizing domain and is 
predicted to contain structural features analogous to the V3 loop of HIV-1 (Ball et al., 
1992).  In this domain, the amino acid sequences of EIAV17 and EIAV19 differ by as 
much as 32.4% (11 out of 34 amino acids).  It is possible that these domains are critical 
for binding of EIAV17 to macrophage surface molecules, and the sequence variations 
result in the inability of EIAV19 to induce cytokines.  Additional studies are needed to 
confirm this hypothesis. 
Since the receptor for EIAV has not been identified, we were unable to directly 
assess the roles of macrophage surface receptor(s) in cytokine induction.  Recombinant 
EIAV17 SU has been successfully expressed in Spodoptera frugiperda (SF9) cells by the 
baculovirus expression system (S. L. Payne, unpublished data).  Investigating the effects 
of purified EIAV17 SU on EMDM cytokines will provide further evidence for the 
mechanism of EIAV17-mediated cytokine induction.   
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CHAPTER V 
 
DISCUSSIONS AND CONCLUSIONS 
 
Discussion 
 
Comparison of RPA to other methods used to analyze equine cytokine expression 
Because equine cytokine reagents are not commercially available, the first goal of 
this study was to develop an assay for quantitating equine cytokine expression.  After 
comparing several methods that have been utilized by other laboratories to analyze 
specific equine cytokines, we concluded that RPA has the features that best serve our 
aims to examine a large variety of cytokines.   
In the past, investigators adapted cell line-based bioassays to measure the secreted 
and biologically active equine cytokines, such as IL-2, IL-6, IFN, TNF-α and TGF-β1 
(MacKay et al., 1991; Morris et al., 1992; Allen et al., 1993; Ellis et al., 1995; Charan et 
al., 1997).  However, these assays are very cumbersome and obviously not suitable for 
screening the response of a large variety of cytokines as required by this study.  
The lack of appropriate antibodies has hindered analysis of equine cytokines by 
immunological assays.  To date, a monoclonal antibody specific to equine TNF-α  and 
an antiserum against recombinant equine IL-8 have been produced and show reactivity 
in immunohistochemistry and dot blot assays, respectively (Franchini et al., 2000; 
Grunig and Antczak, 1995).  However, these antibodies are not commercially 
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distributed.  Detection of equine TGF-β using antibodies specific to human or porcine 
TGF-β has been successful because this gene is highly conserved among different 
species (Chesters et al., 2000; Rodriguez et al., 1996).   
With a rapidly increasing number of published equine cytokines gene sequences, it 
is now feasible to characterize cytokine responses by DNA- or RNA-based techniques.  
For example, RT-PCR, RT-cPCR and Southern blot techniques have been developed to 
measure limited equine cytokine mRNA levels (Grunig and Antczak, 1995; Rottman et 
al., 1996; Byrne et al., 1997; Swiderski et al., 1999; Giguere and Prescott, 1999; 
Leutenegger et al., 1999).  An important advantage of the RPA over other molecular 
techniques is that up to 10-12 cytokines can be simultaneously quantitated when a multi-
probe system is employed.  Although it is possible to detect RNA of multiple genes on a 
single membrane in Northern blot analysis by stripping and reprobing, it is 
comparatively laborious and, more importantly, sensitivity is lost during the process.  
The equine cytokine-specific multi-probe RPA described in this study is capable of 
simultaneously quantitating 10 equine cytokines in a single reaction.  This feature allows 
screening of a large number of cytokines in a time-, reagent-, and sample-saving manner.  
In addition, given that cytokines have redundant functions and complex interactions with 
each other, simultaneous profiling of multiple cytokines is frequently necessary to fully 
assess the contributions of individual cytokines in a physiologically relevant context.  
Another advantage of RPA over Northern blot analysis is its superior sensitivity (Davis 
et al., 1997; Tymms, 1995).  The lysate-based RPA used in this study has been shown to 
detect 104-105 target mRNAs or less than 0.5 molecules per cell (Haines and Gillespie, 
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1992).  The sensitivity of the RPA is only rivaled by RT-PCR based techniques.  
However, the RT-PCR techniques lack the capability of simultaneous detection and are 
best suited for analysis of a limited number of cytokines (Giguere et al., 1999).  They are 
relatively labor-intensive when applied to screening a wide variety of cytokines.  Taken 
together, these features of the RPA make it superior to the other RNA quantitation 
techniques.    
The multi-probe RPA developed in this study simultaneously analyzes the mRNA 
levels of equine IL-1α, IL-1β, IL-6, IL-8, IL-10, IL-12 p35, IL-12 p40, IFN-γ, TGF-β1, 
TNF-α and β-actin (an internal control) in EMDM and EPBMC cultures (Lim et al., 
2003a).  This assay detects as few as 5×105 copies of cytokine RNA molecules and has a 
CV of 0.03-0.08 (or 3%-8%) when using the β-actin mRNA level to normalize the 
sample-to-sample variations. 
 
Relationship between EIAV replication and virulence 
 In EIAV-infected horses, the disease episodes during the acute and chronic 
phases coincide with high titers of viremia (Issel and Coggins, 1979).  In asymptomatic 
animals, the viral load is very low and can only be detected by PCR (Oaks et al., 1998).  
According to a widely accepted model, reduction of EIAV viral load is due to humoral 
and cellular immune responses that clear the predominant viral population, such that a 
new episode of viremia reflects the growth of a different quasispecies that temporarily 
escapes immunologic control (Leroux et al., 1997).  Ultimately, an enduring immunity 
specific to a broad array of EIAV quasispecies is developed, and the animals become 
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clinically asymptomatic.  Upon closer inspection, it is clear that immunity is not the only 
factor that controls viral replication.  For example, the highly virulent EIAVWyo 
replicates to greater levels than the less virulent EIAVWSU and EIAVPV in infected horses 
during both the acute phase, prior to the development of an immune response, and 
during the subclinical phase (Oaks et al., 1998; Harrold et al., 2000).  Studies also show 
that the reduction of viral load in asymptomatic animals is associated with a restriction 
of viral transcription (Oaks et al., 1998; Harrold et al., 2000).  In agreement with these 
findings, levels of HIV-1 transcription in PBMC are shown to be predictive of disease 
progression and severity (Michael et al., 1995; Saksela et al., 1994).  Therefore, it 
appears that not only is EIA disease severity correlated with viral load, but the virulence 
of a virus is also correlated with its in vivo replicative potential.  The replicative 
potential of a virus is presumably a result of interactions between viral and host factors 
that are yet to be identified.  Viral factors that may affect EIAV expression include the 
U3-LTR transcription factor binding motifs and the rev gene (Maury, 1998; Belshan et 
al., 2001).  In comparing HIV-1 RNA sequences between nonprogessive and progressive 
infection, a large deletion is found in the predominant U3-LTR sequences during the 
nonprogressive infection (Fang et al., 2001). The CAT reporter gene assay shows that 
this deletion causes downregulation of LTR-driven transcription in vitro.  At least one 
host cell factor, the B-cell- and macrophage-specific transcription factor PU.1, has been 
shown to control the expression of EIAV in primary equine macrophages (Maury, 1994).   
Cytokines are among the best known host factors that modulate HIV-1 
replication (Fauci, 1996).  The current study demonstrates that the virulent EIAV17 
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induces the expression of IL-1α, IL-1β, IL-6, IL-10 and TNF-α, while the avirulent 
EIAV19 has no effect on these cytokines.  TNF-α is the most thoroughly studied HIV-
inducing cytokine.  It induces HIV-1 transcription by activating the cellular transcription 
factor NF-κB (Fauci, 1996).  IL-1α and IL-1β also enhance HIV transcription 
presumably through NF-κB-independent pathways, and IL-6 upregulates HIV 
production at post-transcriptional levels (Vicenzi et al., 1997).  The effects of IL-10 are 
equivocal.  On the one hand, IL-10 suppresses HIV replication by inhibiting the 
production of pro-inflammatory cytokines (Breen, 2002).  On the other hand, adding IL-
10 at low doses has been shown to enhances HIV replication.  It is likely that the same 
cytokines impact the expression of EIAV.  
In vitro studies of cytokine-regulated EIAV expression have generated 
conflicting results.  Electropheretic mobility shift and CAT reporter gene assays 
demonstrate that the myeloid/B cell-specific transcription factor PU.1 is an important 
regulator of EIAV LTR transcription (Maury, 1994).  As PU.1 is an important 
intermediate for the induction of gene expression by cytokines such as GM-CSF, M-CSF 
and IFN-γ, EIAV transcription may be susceptible to cytokine modulation (DeKoter et 
al., 1998; Nguyen and Benveniste, 2002).  Stimulation of promonocytic cell line U937 
transiently transfected with an EIAV LTR/CAT construct with phorbol myristate acetate 
(PMA) increases CAT activity (Carvalho et al., 1993).  These results support the 
enhancing effects of cytokines on EIAV replication since PMA is a potent inducer of 
macrophage cytokines.  Other investigators report that stimulation of EMDM by PMA or 
bacteria endotoxin, which also induces a wide variety of cytokines, inhibits the 
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production of EIAV (Sellon et al., 1996; Smith et al., 1998).  Although TNF-α 
production is detected following stimulation with PMA or endotoxin, it does not 
correlate with suppression of EIAV replication in the macrophages (Smith et al., 1998).  
PMA-induced downregulation of HIV production in chronically infected promonocytic 
cells is mediated by the activity of IFN-γ, which suppresses HIV maturation and budding 
(Vicenzi et al., 1997).  According to the current study, EIAV17 does not replicate at 
higher levels than EIAV19 in primary equine macrophage cultures, despite its ability to 
induce cytokine expression, suggesting that these cytokines do not directly modulate 
EIAV expression in infected macrophages.   
In contrast to the similar growth rates in culture, EIAV17 replicates to a higher 
titer than EIAV19 in infected Shetland ponies (S. L. Payne, personal communication).  
We speculate that induction of cytokines contributes to the enhanced replication of 
EIAV17 in vivo via paracrine or endocrine actions.  In support of this hypothesis, serum 
levels of two pro-inflammatory cytokines induced by EIAV17, TNF-α and IL-6, are 
shown to positively correlate with EIAV viremia in experimentally infected ponies 
(Sellon et al., 1999; Costa et al., 1997).  Pro-inflammatory cytokines may increase virus 
load in EIAV17-infected animals by recruiting uninfected monocytes to the site of viral 
replication through stimulation of monocyte-chemotactic factors, such as monocyte 
chemoattractant protein-1, 2 and 3 (MCP-1, 2, and 3, respectively), macrophage 
inflammatory proteins 1α (MIP-1α), MIP-1β and RANTES (Wetzel et al., 2002; Tofaris 
et al., 2002; Loghmani et al., 2002; Mukaida et al., 1998).  This mechanism is employed 
by HIV and SIV to recruit target cells to the brain and lymph nodes (Schmidtmayerova 
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et al., 1996; Zink et al., 2001; Wetzel et al., 2002).  HIV and SIV are shown to directly 
stimulate production of chemokines by macrophages, including MCP-1, macrophage 
inflammatory proteins 1α and 1β and RANTES (Wetzel et al., 2002).  Hence, 
investigation of the direct and indirect effects of EIAV17 infection on the expression of 
these cytokines is of great interest.  Other mechanisms by which the EIAV17-induced 
cytokines may enhance viral load in vivo include stimulation of adhesion molecules that 
promote monocyte migration into tissue (Sampson et al., 2002) and expression of EIAV-
activating molecules by non-monocytic cells.   
This study reveals cytokine induction as a distinguishing property for the virulent 
versus avirulent EIAV.  We speculate that this property plays important roles in the 
enhanced viral load and disease severity associated with virulent EIAV infection.  
Conversely, the inability to induce cytokines and reduction of viral expression may be an 
important mechanism for EIAV persistence of avirulent virus.   
 
EIAV virulence determinants 
The viral factors that control the clinical manifestations of EIAV infection are 
unknown.  The successful generation of the virulent EIAV17 clone used in the current 
study is due to the insertion of EIAVWyo LTR, rev and env into avirulent EIAV19 (Payne 
et al., 1998).  The rationale for this modification is that these regions are the “hot spots” 
in the quasispecies evolution of EIAV (Lichtenstein et al., 1996; Belshan et al., 2001; 
Leroux et al., 1997) and the same regions show major sequence differences between the 
virulent EIAV isolates and the avirulent cell culture-adapted viruses (Payne et al., 1994; 
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Perry et al., 1992).  Likewise, the virulent molecular clone (EIAVUK) developed by Cook 
et al. also predominantly differs from its avirulent parental clone in the LTR, rev and 
env, although its construction also involves substitution of the integrase, S1 and S2 genes 
(Cook et al., 1998).  Taken together, it is apparent that one or a combination of these 
factors contains the determinants of EIAV virulence. 
LTR is considered a potential EIAV virulence determinant because a clear 
demarcation between the virulent and avirulent EIAV strains is consistently found in the 
hypervariable regions of the U3 region of the LTR.  Analyses of the consensus LTR 
sequence of the Wyoming wild type strain (EIAVWyo) reveal that its U3 region contains 
3 ets, 1 CREB binding sites and a double CAAT-box motif (Payne et al., 1999; Cook et 
al., 1998).  The U3-LTRs of virulent strains of EIAV, including the virulent molecular 
clones (Payne et al., 1998; Cook et al., 1998), the fibroblast-tropic pathogenic PV strain 
(Cook et al., 1998) and LTRs PCR-amplified from samples of acutely ill EIA horses 
(Maury et al., 1997) are highly homologous to the U3 sequence of Wyoming LTR.  All 
of these virulent LTRs contain 3 ets sites and 1 CREB site and vary only in the number 
of PEA-2 and CAAT-box motifs.  In comparison, the U3 sequences of avirulent EIAVs 
are more divergent from the Wyoming U3-LTR, typically having only 1 to 2 ets sites, 2 
PEA2 sites, 2 CREB site and one CAAT-motif box (Payne et al., 1994; Cook et al., 
1998; Maury et al., 1997; Cook et al., 1998).  Macrophages are the primary sites of 
EIAV replication in vivo, and the ets motifs have been shown to be crucial for EIAV 
LTR-driven transcription in primary equine macrophages (Maury, 1994).  It follows that 
variations in the transcription factors may affect EIAV virulence by altering viral load 
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and/or cell tropism.  Nonetheless, insertion of the U3 sequence derived from the virulent 
PV strain into the LTR of an avirulent EIAV molecular clone fails to generate a virulent 
virus, indicating that LTR is not the sole virulence determinant (Lichtenstein et al., 
1996).  EIAV19 and EIAV17 have U3 LTR sequences that are typical of virulent and 
avirulent EIAV, respectively (Payne et al., 1998).  In particular, EIAV17 carries all 3 to 
the ets motifs while EIAV19 only has 2.  In support of the role of LTR in EIAV 
virulence, lower levels of viremia were observed in the EIAV19-infected animals 
compared to those infected with EIAV17 (F.J. Fuller, unpublished data).  However, the 
current study shows that there is no difference between the growth of EIAV17 and 
EIAV19 in primary equine macrophage culture.  This contradiction emphasizes the 
complex in vivo factors affecting LTR transcription that are not reflected in the in vitro 
system.   
 Rev modulates the expression of structural genes and virion production by 
regulating nuclear export of incompletely spliced viral RNA (Belshan et al., 2000).  It is 
therefore likely that variation in Rev may impact virus load and hence pathogenesis of 
EIAV.  To test this hypothesis, Belshan et al. studied genetic and biological changes of 
rev variants amplified from the inoculum and serum samples collected at different times 
or disease stages of an EIAVWyo-infected horse (Belshan et al., 2001).  The Rev 
quasispecies of the inoculum and the acute and afebrile stages are predominated by the 
same variant, while novel variants appear and predominate during the recurrent and late 
febrile episodes.  Moreover, the predominant Rev variants associated with the febrile 
episodes have significantly higher nuclear export activity than those associated with the 
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acute and afebrile stages, suggesting a correlation between Rev activity and EIA disease 
progression.  Contradictory to the prediction that Rev affects pathogenesis by 
modulating viral replication, Rev activity does not correlate with in vivo virus load 
(Belshan et al., 2001).  Therefore, the mechanism by which Rev alters EIAV 
pathogenicity is still unknown. 
 
Is SU an EIAV virulence determinant? 
We propose that the SU glycoprotein of EIAV is a virulence determinant based 
on (1) the differential effects of EIAV17 and EIAV19 on macrophage cytokine 
expression, as found in the current study; (2) the conferral of virulence to the avirulent 
EIAV19 by insertion of EIAV17 SU; and (3) the differences in the enterotoxic activities 
between purified SU glycoproteins derived from EIAV17 and EIAV19 (J. M. Ball et al., 
unpublished data). 
The current study demonstrates that EIAV17 induces cytokine expression through 
an early event of the infection process.  This process is likely mediated by binding of 
EIAV17 Env protein to the surface molecules of equine macrophages for three reasons.  
First, EIAV17 cytokine induction is replication-independent.  Second, the kinetics of 
induction is strikingly similar to that mediated by binding of HIV-1 gp120 to the CD4 
molecule.  Finally, the most notable differences between EIAV17 and its parental virus 
EIAV19, which fails to induce cytokines, are found in the Env (Payne et al., 1998).  In 
particular, the SU sequences of the 2 viruses diverge by 11 out of 34 amino acids 
(32.4%) in a region of SU containing neutralizing epitopes (the PND) and predicted to 
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be structurally analogous to the HIV-1 V3 loop, a strong inducer of cytokines (Ball et 
al., 1992; Koka et al., 1995).  In close parallel to our findings, Khanna et al. show that a 
molecularly cloned HIV-1 (p125) containing the envelope protein derived from HIVADA, 
the prototypic macrophage-tropic HIV-1 isolated from an AIDS patient, potently induces 
TNF-α in PBMC culture (Khanna et al., 2000).  Insertion of the V3 region from the 
avirulent molecular clone HxBc2 into p125 abrogates it TNF-α-inducing activity.  In 
HIV-1, most of the peptides required for cytokine induction are mapped to the SU 
region(Koka et al., 1995).  Therefore, we propose that SU of EIAV determines the 
ability of the virus to induce cytokines.  Since the cytokines induced by EIAV17 are 
capable of inducing many of the cardinal symptoms of EIA and potentially regulate viral 
expression (as discussed above), it is conceivable that SU may play major roles in the 
pathogenic characteristics of different EIAV strains.   
In a recent study of EIAV virulence determinants, a set of distinct EIAV 
chimeric clones were constructed based on the EIAV19 backbone such that each clone 
contains a different combination of EIAV17 SU, TM and LTR sequences (S. L. Payne et 
al., unpublished data).  Results from infection of Shetland ponies with these viruses 
showed only the clone that derives its LTR and SU sequences from EIAV17 induced 
EIA.  A clone that derives its TM and LTR sequences from EIAV17 but SU sequence 
from EIAV19 is avirulent.  Therefore, in the presence of EIAV17 LTR, SU is more 
important to EIAV virulence than TM.  These results also indicate that the EIAV17 rev 
(overlapped by TM) sequence is not sufficient to impart virulence to EIAV. 
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The notion that the differential abilities of EIAV17 and EIAV19 in causing disease 
can be at least in part attributed to the differences in their SU sequences is supported by 
a study that characterized the enterotoxic activities of EIAV SU (J.M. Ball et al., 
unpublished data).  Due to the recent discovery that SIV SU encodes an enterotoxic 
domain (Swaggerty et al., 2000), SU derived from EIAV17 and EIAV19 (termed vSU and 
avSU, respectively) were expressed in a baculovirus expression system, purified and 
tested for diarrhea induction in a mouse model.  While vSU induced diarrhea in a dose-
dependent manner with a diarrhea dose 50 (DD50) of 0.14 nmols, the dose of avSU 
sufficient to induce diarrhea in at least 50% of animals could not be attained.  To 
determine whether the EIAV SU acts as an enterotoxin, vSU and avSU were assessed 
and compared for their effects on intestinal fluid accumulation in ligated loops, chloride 
secretory current as measured in Ussing chamber, and intracellular signal transduction.  
The average vSU-treated intestinal loops were 60.8 mg/cm, compared to the average of 
55.4 mg/cm for the avSU-treated loops.  Addition of 1.5 µM of vSU or avSU to the 
basolateral and apical sides of mouse intestines induced a forskolin-potentiated short-
circuit chloride current of 2.41 or 1.25 µA/cm2, respectively.  Finally, treating HT-29 
cells (human colon adenocarcinoma) with 150 nM of vSU or avSU increased inositol 
triphosphate levels by 2.26 or 1.47 fold above basal levels, respectively.  In summary, 
this study reveals that EIAV SU is an enterotoxin and, more importantly, that there are 
differences in the intrinsic pathogenic properties of vSU and avSU, which may 
contribute to the difference in clinical outcome of EIAV17 and EIAV19 infection.   
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The role of the envelope glycoprotein as a virulence determinant has been shown 
in simian-human immunodeficiency virus (SHIV), a chimeric SIV containing tat, rev, 
vpu and env of HIV-1 used for studying HIV-1 pathogenesis in simian models 
(Cayabyab et al., 1999).  SHIV-HXBc2, a molecularly cloned SHIV containing env of 
cell line adapted HIV-1 isolate, is avirulent in rhesus monkey.  Replacing the env of 
SHIV-HXBc2 with env sequences derived from a pathogenic HIV isolate generates a 
highly virulent virus (SHIV-HXBc2P 3.2) that causes AIDS-like symptoms within 2 
years of infection.  The two viruses differ only in 12 amino acids in the envelope 
glycoprotein, 10 of which are located in the SU region.  The same study demonstrates 
that the envelope glycoprotein of SHIV-HXBc2P 3.2 contributes to virulence by 
enhancing early events during the infection cycle, leading to higher levels of replication 
both in vivo and in cultured PBMC.  It is also proposed that the envelope glycoprotein of 
SHIV-HXBc2P 3.2 is more efficient at destroying CD4+ T cells (Cayabyab et al., 1999).   
Despite the apparent efficacy of virulent SU in mediating disease, we do not rule 
out the possibility that EIAV virulence is a phenotype that involves multiple viral 
factors.  For example, in the study of EIAV virulence determinants described above, a 
chimeric clone that derives it env from EIAV17 and LTR from EIAV19 failed to cause 
disease in Shetland ponies (S. L. Payne, unpublished data).  EIAV encoding the virulent 
SU may not attain the viral load that is sufficient for exerting its pathological effects if 
the appropriate LTR sequence is absent.   
 
 
110
Pitfalls and Problems 
Since equine cytokine-specific antibodies are unavailable, RPA was employed to 
to characterize cytokine responses by measuring mRNA transcription levels.  
Measurement of cytokine mRNA expression by RPA, which is highly sensitive to 
nucleotide mismatches, may be affected by polymorphisms of cytokine genes.  More 
importantly, production of some cytokine, such as TGF-β1, is regulated by post-
transcriptional processes including stabilization of mRNA and activation of precursor 
proteins by extracellular enzymes (Toossi et al., 1995).  This implies that the 
transcription level of TGF-β1 genes may not directly correlate to the production of 
biologically active TGF-β1 molecules.  Similarly, IL-1β and IL-1α transcripts may 
accumulate intracellularly in the absence of protein secretion (Zhong et al., 1993).  
Therefore, the induction of cytokine mRNA is only an indicator of increased cytokine 
production and should be interpreted with caution.  However, this study screened the 
response of a large number of equine cytokines and identified five cytokines that warrant 
further investigation.  It will now be feasible to produce equine cytokine specific 
antibodies or perform bioassays to quantitate the secreted molecules with the relevant 
cytokines known.   
The most significant problem in this study is the lack of an equine macrophage 
cell line.  The primary equine macrophage culture is time-consuming, labor-intensive 
and technically demanding.  As macrophages were isolated from different out-bred 
animals for each experiment, there was a great deal of variability in their viability in 
culture, ability to produce EIAV and constitutive cytokine expression levels.  Occasional 
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shortage of horse donors caused a delay in research progress.  The high degree of 
variability and low numbers of animals rendered statistical analysis of the data difficult.  
This difficulty was met by employing the linear-mixed effects model in data analysis, 
which takes into account the random effects of individual animals.  Remarkably, the 
trends of cytokine responses to EIAV17 and EIAV19 were highly consistent and 
reproducible in macrophages that originated from different horses, indicating the 
generality of the results.  Although derivation of an equine macrophage cell line may 
greatly facilitate future experiments, precautions must be taken when comparing the 
response to EIAV infection to that of mature equine macrophages as macrophage 
differentiation apparently has major impact on the life cycle of EIAV. 
 Another issue related to use of macrophage culture is the inability of the in vitro 
system to reflect the complexity of the in vivo conditions.  This shortcoming was made 
apparent by the discrepancy between the in vitro and in vivo growth rate of the EIAV 
molecular clones.  More importantly, cytokines are not exclusively produced by 
macrophages.  Other important sources of cytokines such as the lymphocytes, dendritic 
cells and endothelial cells are not included in the macrophage culture system.  Cytokines 
produced by macrophages influence the synthesis of cytokines by other cells, which may 
in turn influence production and activities of macrophage cytokines, forming a complex 
network of interacting molecules.  For example, in characterizing the RPA, it was 
observed that lipopolysaccharide (LPS) failed to stimulate IL-12 p35 and IL-12 p40 
expression, which was surprising since macrophages are a main source of IL-12 
(Cavaillon, 1994).  This discrepancy is likely because LPS-induced expression of IL-12 
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requires priming by IFN-γ, which is mainly produced by stimulated lymphocytes (Hayes 
et al., 1995).  Therefore, to assess cytokine responses under more physiological 
conditions, cells and tissue samples collected from EIAV-infected animals should be 
analyzed.  However, the distinct advantage of using primary macrophage culture is that 
the results represent the response of a defined population of cells to EIAV infection.  It is 
especially important to understand the cytokine profiles of macrophages since they are 
the predominant targets for EIAV infection.  These profiles also help predict potentially 
affected genes and cellular functions that can be examined in future studies.   
One weakness of this study is the lack of evidence for the mechanism of cytokine 
induction.  Based on the rapid kinetics of EIAV17-induced cytokine response, I 
hypothesized that binding of SU to macrophage surface receptor(s) is responsible for 
EIAV17-induced cytokine expression.  Providing direct evidence for this hypothesis was 
difficult in part because the cellular receptor for EIAV is unknown and consequently 
could not be blocked.  I demonstrated that cytokine induction by EIAV17 does not 
require viral replication, as would be expected for effects mediated by receptor binding.  
The effort to demonstrate the effects of SU on cytokine expression was hampered by the 
difficulties in maintaining the solubility of purified SU, likely due to protein 
aggregation.  As discussed earlier, a synthetic peptide corresponding to the VH region of 
SU did not induce cytokine expression when added to EMDM.  At present, different 
techniques to purify soluble SU and alternative approaches to test the effects of SU are 
being explored.  While more evidence is clearly needed, the existing results indicate the 
cytokine-inductive activities of EIAV closely parallel those of HIV-1, which is well 
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established to induce cytokines via binding of SU glycoprotein to its cellular receptor, 
the CD4 molecule (Cicala et al., 2002). 
 
Future studies 
 
Mechanisms of cytokine induction by EIAV 
Although both rapid kinetics and dispensability of viral replication suggest that 
EIAV17 induction of cytokine expression is mediated by binding of the envelope 
glycoprotein, direct evidence for the mechanism(s) of cytokine induction is needed.  
Soluble Env, SU and TM proteins derived from EIAV17 and EIAV19 could be expressed 
and tested for their induction of cytokines in equine macrophages.  These experiments 
would provide definitive evidence that cytokines are induced by the viral envelope 
glycoprotein as well as provide a means to identify the cytokine-inductive subunit.  
Modifications such as truncation of the proposed transmembrane domain of TM might 
be necessary to allow secretion of Env and TM.  Another method to approach this 
question is to insert env, SU or TM, derived from EIAV17 into the non-cytokine-inducing 
EIAV19.  Pseudotyped viruses expressing EIAV17 env genes could also be used.  
Chimeric and pseudotyped viruses have advantages over purified proteins in mimicking 
native protein structures.  Accurate representation of protein structure is especially 
important considering that EIAV Env is likely to assemble into trimers, as is the case 
with HIV-1 Env, and that the trimeric structure is critical for the formation of HIV-1 Env 
receptor binding sites.  To further characterize the cytokine inductive regions of EIAV 
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Env, truncation or substitution mutants of SU or TM could be generated and compared 
for cytokine stimulation.  Synthetic peptides corresponding to different domains of Env 
could also be used to determine the sequences involved in cytokine induction.  Because 
peptides are linear and are not post-translationally modified, these experiments would 
provide insight into the importance of conformation, oligomerization and glycosylation 
in the cytokine-inductive activities of the envelope proteins.  However, this approach 
could be problematic since macrophages may phagocytose or pinocytose the peptides.   
A peptide (EIAV6) corresponding to the VH region of EIAV17 SU was 
synthesized, HPLC-purified, characterized by mass spectrophotometry and added to 
primary equine macrophages.  Shown below is the sequence of the peptide. 
EIAV6: EDNKGVVRGDYTACNVRRLNINRKDYTGIYQVP 
This peptide was selected because it was shown to be biologically active in 
mouse diarrhea experiments (J. M. Ball, unpublished data).  Although the peptide failed 
to stimulate cytokines at 20 and 200 nmol per ml, the importance of this region in 
cytokine induction cannot be ruled out as the result may reflect that linear amino acid 
sequence is not sufficient for receptor recognition.  Alternatively, the peptide may enter 
macrophages without binding to the receptor, as shown with the SIV enterotoxic peptide 
(C. L. Swaggerty et al., unpublished data).  Testing the inhibitory effects of this peptide 
on EIAV17- or purified envelope protein-induced cytokine expression would yield 
interesting information regarding contribution of VH to cytokine induction.  Elucidation 
of the cytokine induction mechanisms would provide new concepts for design of 
protective vaccines and reveal potential therapeutic targets and strategies. 
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Other cytokines dysregulated by EIAV infection 
This study reveals striking resemblance between EIAV and HIV-1 in the 
cytokine-pathogenesis relationship.  Therefore, analyses of other cytokines known to be 
important in HIV-1 disease progression are warranted.  Among these cytokines, the 
expression of β-chemokines MIP-1α, MIP-1β, MCP’s and RANTES in primary equine 
macrophage infected by EIAV17 and EIAV19 deserves immediate investigation.  These 
molecules are believed to downregulate HIV-1 replication by blocking the CCR5 
coreceptor (Vicenzi et al., 1997).  More importantly, they are monocyte/macrophage 
chemoattractants that may enhance EIAV viral load in vivo by recruiting target cells to 
the site of viral replication.  Given that transcription of EIAV in primary equine 
macrophages appear to be regulated by binding of the PU.1 transcription factor to the ets 
sites of U3-LTR (Maury, 1994), it would be interesting to examine the expression of 
granulocyte-monocyte and monocyte colony-stimulating factors (GM-CSF and M-CSF, 
respectively), which activate PU.1 upon binding to their cellular receptors (DeKoter et 
al., 1998).  Furthermore, these cytokines regulate the differentiation and maturation of 
monocytic cells, which are processes known to activate the expression of EIAV (Maury, 
1994).  Partial or complete cDNA sequences of equine GM-CSF, RANTES, and MCP’s 
are available in Genbank and can be used to generate RNA probes for RPA analysis.  
Cloning and sequencing of equine MIP-1α, MIP-1β and M-CSF can be performed by 
designing primers corresponding to the most conserved regions of these genes.   
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Roles of cytokines in EIAV immunology 
Both humoral and cellular immunity are involved in the host response to EIAV 
infection.  The humoral immune response to EIAV antigens and the importance of 
neutralizing antibodies in controlling viral replication have been discussed earlier.  In 
EIAV-infected animals, neutralizing antibodies specific to the infecting strains are not 
detected until 2-3 months post-infection, whereas virus-specific CTL appears within 3-4 
weeks post-infection and coincides with resolution of the initial viremia, emphasizing 
the importance of CTL in viral clearance during acute infection (Hammond et al., 1997).  
It is hypothesized that HIV disease progression is the consequence of a “shift” from the 
protective CTL response that effectively controls viral replication to the potentially 
harmful humoral immune response (Poli et al., 1995).  Analysis and comparison of the 
horse immune responses involved in managing EIAV17 and EAIV19 infection would 
provide new concepts for EIAV pathogenesis and vaccine design.   
According to the mouse Th1/Th2 paradigm, Th1 are CD4+ T cells that promote 
CTL response by secreting IL-2 and IFN-γ.  In contrast, Th2 cells promote humoral 
immune response by secreting IL-4 and IL-5.  Fraser et al. showed that Gag peptides 
containing broadly recognized CTL epitopes selectively stimulate IFN-γ but not IL-4 
expression by PBMC of EIAV-infected horses (Fraser et al., 2002).  Thus, it appears that 
the Th1/Th2 dichotomy exists in the horse immune system, and the cytokine profiles of 
PBMC can be used as indicators for Th1 versus Th2 immune response to EIAV antigens.   
The Th1/Th2 phenotype of CD4+ T cells in horses infected with EIAV17 and 
EIAV19 could be characterized by analyzing expression of cytokines that distinguish Th1 
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(IL-2 and IFN-γ) and Th2 (IL-4, IL-5) responses in PBMC isolated from infected horses.  
Analyzing PBMC cytokines isolated at different stages of EIA and stimulated with 
different EIAV antigens would yield interesting information regarding the evolution and 
mechanisms of immune response to these viruses.  I expect PBMC of EIAV17- and 
EIAV19-infected horses to display distinct cytokine profiles since the differentiation of 
the Th1/Th2 subsets are heavily influenced by cytokines secreted by EIAV17-infected 
macrophages.  For example, IL-1 and TNF-α stimulate IL-2 production, which is 
associated with the Th1 phenotype.  On the other hand, IL-10 is regarded as a Th2 
cytokine since it inhibits the Th1 response.  In addition, Env contains epitopes that are 
frequently recognized by CTL of infected horses, variation of Env sequences between 
EIAV17 and EIAV19 may impact these epitopes (McGuire et al., 2000).   
 
Pathogenic roles of cytokines in EIAV diseases 
I speculate that the cytokines induced by EIAV17 in primary equine macrophages 
contribute to its virulence based on the following three reasons.  First, the differential 
abilities of EIAV17 and EIAV19 in stimulating these cytokines in vitro mirror their 
differential abilities to cause diseases in vivo.  Second, the pathological changes 
associated with dysregulation of these cytokines mimic the principal symptoms of EIA 
such as fever, thrombocytopenia and anemia (Powell et al., 1996).  The contributions of 
cytokines to these EIA symptoms are supported by results of previous studies (Tornquist 
and Crawford, 1997; Costa et al., 1997).  Finally, cytokines have been implicated in 
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pathogenesis of HIV-1 disease similar to those of EIAV (Chang et al., 1998; Means, 
1997; Zauli et al., 1992).   
The role(s) of cytokines in EIA could be tested by in vitro and in vivo 
experiments.  Establishment of equine bone marrow culture for assessing the growth of 
megakaryocyte colonies and erythrocyte progenitors has been described previously 
(Swardson et al., 1992; Tornquist and Crawford, 1997).  Equine macrophage culture 
could be exposed to EIAV17 or EIAV19 to stimulate cytokine expression, and the 
conditioned culture supernatants could be tested for their effects on the proliferation and 
differentiation of megakaryocyte colonies and erythrocyte progenitors.  These 
experiments would indicate whether the secretory products of EIAV-stimulated 
macrophages have suppressive effects on platelet and erythrocyte production.  
Contribution of cytokines to thrombopoiesis and erythropoiesis suppression could be 
determined by whether addition of cytokine-specific neutralizing antibodies reverses the 
suppressive activities.  Since such equine cytokine-specific antibodies are not 
commercially available, cross-reactive or pan-specific antibodies would have to be used.  
Alternatively, equine cytokine-specific antibodies could be generated de novo.   
Another means to demonstrate that cytokines mediate EIA diseases is to 
experimentally infect horses with EIAV and examine the correlation between elevation 
of cytokine expression and development of symptoms.  Cytokine mRNA levels should 
be analyzed in tissue or bone marrow macrophages, the sites of active EIAV replication, 
instead of peripheral monocytes (Sellon et al., 1992; Swardson et al., 1997).  Cytokine 
expression levels could be compared between horses infected with virulent EIAV versus 
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those infected with avirulent EIAV.  Correlation between cytokines levels and disease 
severity as well as temporal correlation between cytokine elevation and onset of 
symptoms could also be examined.  However, these data would be suggestive rather than 
conclusive. 
 
Advancement of Equine Immunology and EIAV Pathogenesis 
This study has advanced the field of equine immunology by developing a multi-
probe RPA that simultaneously quantitates the mRNA levels of 10 equine cytokines, 
using the equine β-actin gene as an internal control.  This assay was carefully validated 
and shown to be highly specific, reproducible and sensitive.  It is a valuable tool for 
equine cytokine research as equine cytokine reagents are not commercially available.  In 
fact, these probes have been used in a study of neonatal foal immune development by 
measuring PBMC cytokines over the first few weeks of life (Boyd et al., 2003).  This 
study incorporates two additional cytokine probes to the template set (total of 12 
cytokines) and labels the probes by biotin instead of radioactive isotopes, demonstrating 
the versatility of this assay.   
 The findings of this study establish cytokine induction as an in vitro biological 
property that differentiate the virulence of EIAV isolates.  Previously, EIA was 
hypothesized to be largely an immune complex disease.  This hypothesis is supported by 
little or no evidence and is further undermined by the observation of severe EIA in 
infected SCID horses.  The potential roles of cytokines in EIAV virulence provide a new 
concept for the mechanisms of EIA diseases.  However, the proposition of cytokines as 
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disease mediators does not exclude the involvement of specific immune responses.  
Rather, the fact that cytokines are essentially immune regulatory molecules bespeaks 
that this concept will also bring new insight into the roles of the immune response in 
EIAV pathogenesis. 
Finally, the use of molecularly cloned viruses in this study allowed for 
identification of SU as a virulence determinant.  Although more studies are needed to 
confirm that the virulent SU alone is sufficient to induce cytokines, the reasoning that 
variations in the SU sequences differentiate the pathogenic properties of the 2 EIAV 
clones is in line with the results of previous functional and genetic studies on EIAV SU.  
This finding is valuable for development of therapeutic strategies and design of future 
vaccines.   
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